CURRICULUM VITAE Frederick G. Hayden, M.D ... - Common Cold · 1 CURRICULUM VITAE Frederick G....
37
1 CURRICULUM VITAE Frederick G. Hayden, M.D., F.A.C.P. Address: University of Virginia Health System Box 800473 Dept. of Internal Medicine Hospital Drive, Private Clinics, Rm 6557 Charlottesville, Virginia 22908 University of Virginia Respiratory Disease Study Unit 400 Brandon Ave – G020 P. O. Box 800760 Charlottesville, VA 22908 Personal: Born 11 January, 1948, Madison, Wisconsin Education: 1966-68 1968-69 1971 1969-73 University of Wisconsin, Madison Wisconsin Albert Ludwigs University, Freiburg, Germany B.A., Stanford University, Stanford, California M.D., Stanford University School of Medicine, Stanford, California Postdoctoral Training: 1973-74 1974-76 1976-78 Intern in Medicine, Strong Memorial Hospital, Rochester, New York, (Dr. Lawrence E. Young) Resident in Medicine, Strong Memorial Hospital, Rochester, New York (Dr. Daniel Kimburg and Dr. William Morgan) Trainee and Fellow in Infectious Diseases, University of Rochester School of Medicine, Rochester, New York (Dr. R. Gordon Douglas, Jr. and Dr. William Morgan) Postdoctoral Certification: 1974 1976 1982 National Board of Medical Examiners American Board of Internal Medicine Subspecialty Board in Infectious Diseases Licensure: 1978- Virginia Academic Appointments: 1978-84 1984-90 1986-90 1988-89 1990- Assistant Professor of Internal Medicine and Pathology, University of Virginia School of Medicine, Charlottesville, Virginia Associate Professor of Internal Medicine and Pathology, University of Virginia School of Medicine Chairholder, Stuart S. Richardson Professorship of Clinical Virology in Internal Medicine, University of Virginia School of Med. Attached Worker, Division of Virology, National Institute for Medical Research, London, England (Dr. Alan J. Hay and Dr. John J. Skehel) Stuart S. Richardson Professor of Clinical Virology in Internal Medicine and Professor of Internal Medicine and Pathology, University of Virginia School of Medicine, Charlottesville, Virginia Administrative Appointments: 1978-2001 1986- Associate Director, Clinical Microbiology Laboratory (Virology), University of Virginia Health Sciences Center Associate Director, Respiratory Disease Study Unit, The Center for The Prevention of Disease and Injury, University of Virginia
Transcript of CURRICULUM VITAE Frederick G. Hayden, M.D ... - Common Cold · 1 CURRICULUM VITAE Frederick G....
1
CURRICULUM VITAEFrederick G. Hayden, M.D., F.A.C.P.
Address: University of Virginia Health SystemBox 800473 Dept. of Internal MedicineHospital Drive, Private Clinics, Rm 6557Charlottesville, Virginia 22908
University of Virginia Respiratory Disease Study Unit400 Brandon Ave – G020P. O. Box 800760Charlottesville, VA 22908
Personal: Born 11 January, 1948, Madison, Wisconsin
Education: 1966-681968-6919711969-73
University of Wisconsin, Madison WisconsinAlbert Ludwigs University, Freiburg, GermanyB.A., Stanford University, Stanford, CaliforniaM.D., Stanford University School of Medicine, Stanford, California
PostdoctoralTraining:
1973-74
1974-76
1976-78
Intern in Medicine, Strong Memorial Hospital,Rochester, New York, (Dr. Lawrence E. Young)Resident in Medicine, Strong Memorial Hospital,Rochester, New York (Dr. Daniel Kimburg and Dr. William Morgan)Trainee and Fellow in Infectious Diseases, University of Rochester Schoolof Medicine, Rochester, New York (Dr. R. Gordon Douglas, Jr. and Dr.William Morgan)
PostdoctoralCertification:
197419761982
National Board of Medical ExaminersAmerican Board of Internal MedicineSubspecialty Board in Infectious Diseases
Licensure: 1978- Virginia
AcademicAppointments:
1978-84
1984-90
1986-90
1988-89
1990-
Assistant Professor of Internal Medicine and Pathology,University of Virginia School of Medicine, Charlottesville, VirginiaAssociate Professor of Internal Medicine andPathology, University of Virginia School of MedicineChairholder, Stuart S. Richardson Professorship of ClinicalVirology in Internal Medicine, University of Virginia School of Med.Attached Worker, Division of Virology, National Institute for MedicalResearch, London, England (Dr. Alan J. Hay and Dr. John J. Skehel)Stuart S. Richardson Professor of Clinical Virology in Internal Medicineand Professor of Internal Medicine and Pathology,University of Virginia School of Medicine, Charlottesville, Virginia
AdministrativeAppointments:
1978-2001
1986-
Associate Director, Clinical Microbiology Laboratory (Virology),University of Virginia Health Sciences CenterAssociate Director, Respiratory Disease Study Unit, The Center for ThePrevention of Disease and Injury, University of Virginia
2
Committees: 1984-88
1988-
1988-
1994-1998-
Member, Human Investigation Committee,University of Virginia Medical CenterMember, HIV and AIDS Advisory Committee,University of Virginia Health Sciences CenterMember, Infection Control Committee,University of Virginia Health Sciences CenterMember, Promotions Committee, Department of Internal MedicineMember, Pharmacy and Therapeutics Antimicrobic Subcommittee,University of Virginia Health Sciences Center
EditorialBoards:
1985-901990-951985-1989-001992-011995-1999-2001-
Antimicrobial Agents and ChemotherapyEditor, Antimicrobial Agents and ChemotherapyAntiviral ResearchAntiviral Chemistry and ChemotherapyInternational Antiviral NewsAntiviral TherapyInternational Journal of Antimicrobial AgentsJournal of Antimicrobial Chemotherapy
Other: 1978-861994-99
1995-981995-1996-1999-20001998-
USA-USSR Joint Scientific Exchange ProgramProgram Committee, Interscience Conference on Antimicrobial Agents andChemotherapy, American Society for MicrobiologyExecutive Committee, International Society of ChemotherapyExecutive Committee, NIAID Collaborative Antiviral Study GroupBoard of Directors, International Society for Antiviral ResearchCo-Chair, Harold C. Neu Infectious Diseases ConferenceCo-Chair, I-IV International Symposia on Influenza and Other RespiratoryViruses
Honors: 1969197319962001
Phi Beta Kappa, University of WisconsinAlpha Omega Alpha, Stanford UniversityJames H. Nakano Citation, Centers for Disease Control and PreventionClinical Virology Award, Pan American Society for Clinical Virology
ProfessionalSocieties:
American Academy of Microbiology (Fellow, 1994)American College of Physicians (Fellow, 1982)American Federation for Clinical ResearchAmerican Society for Clinical Investigation (1992)American Society for MicrobiologyAmerican Society for VirologyAmerican Association for the Advancement of SciencesInfectious Diseases Society of America (Fellow, 1986)International Society for Antiviral ResearchPan American Group for Rapid Viral DiagnosisSouthern Society for Clinical Investigation (1986)
Bibliography
3
Original Articles
1. Hayden FG, WJ Hall, RG Douglas Jr, and DM Speers. Amantadine aerosols in normal volunteers;pharmacology and safety testing. Antimicrob Agents Chemother 16:644-650, 1979.
2. Douglas RG Jr, LJ Markoff, BR Chanock, RF Betts, FG Hayden, MM Levine, GA Van Blerk, SBScotman, and DR Nalin. Live Victoria/75-ts-1 [E] influenza A virus vaccines in adult volunteers: Role ofhemagglutinin immunity in protection against illness and infection caused by influenza A virus. InfectImmun 26:275-279, 1979.
3. Hayden FG, WJ Hall, and RG Douglas Jr. Therapeutic effect of aerosolized amantadine HCl in naturallyacquired influenza A virus infection. J Infect Dis 141:535-542, 1980.
4. Hayden FG, MK Cote, and RG Douglas Jr. Plaque inhibition assay for susceptibility testing of influenzaviruses. Antimicrob Agents Chemother 17:865-870, 1980.
5. Hayden FG, RG Douglas Jr, and R Simons. Enhancement of activity against influenza viruses bycombination of antivirals. Antimicrob Agents Chemother 18:536-541, 1980.
6. VanVoris LP, RB Betts, FG Hayden, WA Christmas, and RG Douglas Jr. Successful treatment ofnaturally occurring influenza A/USSR/77 H1N1. J Amer Med Assoc 245:1128-1131, 1981.
7. Hayden FG, B Giordani, JM Gwaltney Jr, RL Van de Castle, and KF Adams. Comparative toxicity ofamantadine HCl and rimantadine HCl in healthy adults. Antimicrob Agents Chemother 19:226-233, 1981.
8. Gigliotti F, WT Williams, FG Hayden, and JO Hendley. Etiology of acute conjunctivitis in children. JPediatr 98:531-536, 1981.
9. Whitley RJ, SJ Soong, MS Hirsch, AW Karchmer, R. Dolin, G Galasso, JK Dunnick, CA Alford Jr, andthe NIAID Collaborative Antiviral Study Group [FG Hayden]. Herpes simplex encephalitis: vidarabinetherapy and diagnostic problems. N Engl J Med 304:313-318, 1981.
10. Whitley, RJ, J Tilles, C Linneman, C Liu, G Pazin, M Hilty, J Overall, AM Visintine, SJ Soong, CAAlford Jr, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Herpes simplex encephalitis:clinical assessment. J Amer Med Assoc 247:317-318, 1981.
11. Hayden FG and JM Gwaltney. Prophylactic activity of intranasal enviroxime experimentally inducedrhinovirus type 39 infection. Antimicrob Agents Chemother 21:892-897, 1982.
12. Hayden FG, DM Zyldikov, VI Iljenko, and YV Padolka. Comparative therapeutic effect of aerosolized andoral rimantadine HCl in experimental human influenza A virus infection. Antiviral Res 2:147-153, 1982.
13. Powers RD, JM Gwaltney Jr, and FG Hayden. Activity of MDL-860 [2-(3,4, dichlorophenoxy)-4-nitrobenzonitrile] against picornaviruses . Antimicrob Agents Chemother 22:639-642, 1982.
14. Whitley RJ, SJ Soong, R Dolin, R Betts, C Linneman, CA Alford Jr, and the NIAID CollaborativeAntiviral Study Group [FG Hayden]. Early vidarabine therapy to control the complications of herpes zosterin immunosuppressed patients. N Engl J Med 307:971-975, 1982.
15. Nahmias AJ, RJ Whitley, AN Visintine, Y Takei, CA Alford Jr, and the NIAID Collaborative AntiviralStudy Group [FG Hayden]. Herpes simplex virus encephalitis: laboratory evaluations and their diagnosticsignificance. J Infect Dis 145:829-836, 1982.
16. Powers RD, MF Rein, and FG Hayden. Necrotizing balanitis due to herpes simplex type 1. J Amer MedAssoc 248:215-216, 1982.
Bibliography
4
17. Hayden FG, HE Hoffman, and DA Spyker. Differences in amantadine HCl and rimantadine HCl toxicitiesrelate to differences in pharmacokinetics. Antimicrob Agents Chemother 23:458-464, 1983.
18. Turner RB, FG Hayden, and JO Hendley. Counterimmunoelectrophoresis of urine for diagnosis of bacterialpneumonia in pediatric outpatients. Pediatr 71:788-790, 1983.
19. Hayden FG and JM Gwaltney Jr. Antiinterferon antibody increases rhinovirus isolation rates from nasalwash samples containing interferon. Antiviral Res 3:67-71, 1983.
20. Hayden FG, AS Sorensen, and JA Bateman. Comparison of the Immulok Cultureset kit and virusisolation for detection of herpes simplex virus in clinical specimens. J Clin Microbiol 18:222-224, 1983.
21. Powers RD, WM Dotson Jr, and FG Hayden. Modification of encephalomyocarditis virus-induced diabetesin mice by antiviral agents. Antiviral Res 3:151-159, 1983.
22. Hayden FG and JM Gwaltney Jr. Intranasal interferon-alpha2 for the prevention of rhinovirus infection andillness. J Infect Dis 148:543-550, 1983.
23. Farr BM, JM Gwaltney Jr, FG Hayden, and GL Mandell. Human polymorphonuclear neutrophil functionsare unaffected by recombinant DNA interferon. Infect Immun 42:1195-1197, 1983.
24. Hayden FG, SE Mills, and ME Johns. Human tolerance and histopathologic effects of chronic intranasalinterferon-alpha2. J Infect Dis 148:914-921, 1983.
25. Helzlsouer KJ, FG Hayden, and AD Rogol. Severe metabolic complications in a cross country runner withsickle cell trait. J Amer Med Assoc 249:777-779, 1983.
26. Whitley RJ, S Spurance, FG Hayden, J Overall, CA Alford Jr, JM Gwaltney Jr, S-J Soong, and theNIAID Collaborative Antiviral Study Group. Vidarabine therapy of mucocutaneous herpes simplex virusinfections in the immunocompromised host. J Infect Dis 149:1-8, 1984.
27. Hayden FG, AN Schleupushkin, and NL Pushkarskaya. Combined interferon-alpha2, rimantadine HCl, andribavirin inhibition of influenza virus replication in vitro . Antimicrob Agents Chemother 25:53-57, 1984.
28. Powers RD, FG Hayden, J Samuelson, and JM Gwaltney Jr. Immune response of adults to sequentialinfluenza vaccination. J Med Virol 14:169-175, 1984.
29. Farr BM, JM Gwaltney Jr, KF Adams, and FG Hayden. Intranasal interferon-alpha2 for prevention ofnatural rhinovirus colds. Antimicrob Agents Chemother 26:31-34, 1984.
30. Hayden FG and JM Gwaltney Jr. Intranasal interferon-alpha2 treatment of experimental rhinovirus colds. JInfect Dis 150:174-180, 1984.
31. Hayden FG, JM Gwaltney Jr, and ME Johns. Prophylactic efficacy and tolerance of low dose intranasalinterferon-alpha2 in natural respiratory viral infections. Antiviral Res 5:111-116, 1985.
32. Brandt SJ, CG Tribble, AD Lakeman, and FG Hayden. Herpes simplex burn wound infection:epidemiology of a case cluster and response to acyclovir therapy. Surgery 98:338-343, 1985.
33. Hayden FG, A Minocha, DA Spyker, and HE Hoffman. Comparative, single-dose pharmacokinetics ofamantadine hydrochloride and rimantadine hydrochloride in young and elderly adults. Antimicrob AgentsChemother 28:216-221, 1985.
34. Geist FC and FG Hayden. Comparative susceptibilities of strain MRC-5 human embryonic lung fibroblast
Bibliography
5
cells and the Cooney strain of human fetal tonsil cells for isolation of rhinovirus from clinical specimens. JClin Microbiol 22:455-456, 1985.
35. Quinn SF, S Erickson, D Oshman, and FG Hayden. Lobar collapse with respiratory syncytial viruspneumonitis. Pediatr Radiol 15:229-230, 1985.
36. Hayden FG, J Albrecht, D Kaiser, and JM Gwaltney Jr. Prevention of natural colds by contact prophylaxiswith intranasal alpha2-interferon. N Engl J Med 314:71-75, 1986.
37. Whitley RJ, CA Alford, MS Hirsh, TR Schooley, JP Luby, FR Aoki, D Hanley, AJ Nahmias, S- JSoong, and the NIAID Collaborative Study Group [FG Hayden]. Vidarabine versus acyclovir therapy inherpes simplex encephalitis. N Engl J Med 314:144-149, 1986.
38. Hayden FG and AS Monto. Oral rimantadine hydrochloride therapy of H3N2 subtype influenza virusinfection in adults. Antimicrob Agents Chemother 29:339-341, 1986.
39. Wenzel RP, FG Hayden, DHM Groshell, RA Salata, WS Young, JE Greenlee, S Newman, PJ Miller, KEHechemy, W Burgdorfer, MG Peacock, and LJ Rubinstein. Acute febrile cerebrovasculitis: a syndrome ofunknown, perhaps Rickettsial, cause. Ann Intern Med 104:606-615, 1986.
40. Gaffey MJ, JM Gwaltney Jr, WE Dressler, JV Sorrentino, and FG Hayden. Intranasal atropine methonitratetreatment of experimental rhinovirus colds. Am Rev Resp Dis 135:241-244, 1987.
41. Winther B, DF Innes, SE Mills, N Mygind, D Zito, and FG Hayden. Lymphocyte subsets in normalairway mucosa of the human nose. Arch Otolaryngology Head Neck Surg 113:59-62, 1987.
42. Hurley PT, RA Salata, and FG Hayden. Chronic gonococcal osteomyelitis. South Med J 80:264-266,1987.
43. Geist FC, Bateman JS, and FG Hayden. In vitro activity of zinc salts against human rhinoviruses.Antimicrob Agents Chemother 31:622-624, 1987.
44. Hayden FG, B Winther, GR Donowitz, SE Mills, and DJ Innes. Human nasal mucosal responses totopically applied recombinant leukocyte A interferon. J Infect Dis 156:64-72, 1987.
45. Stein DS, CM Creticos, GG Jackson, JM Bernstein, FG Hayden, GM Schiff and DI Bernstein. Oralribavirin treatment of influenza A and B. Antimicrob Agents Chemother 31:1285-1287, 1987.
46. Gaffey MJ, JM Gwaltney Jr, A Sastre, WE Dressler, JV Sorrentino, and FG Hayden. Intranasal and oralantihistamine treatment of experimental rhinovirus colds. Amer Rev Resp Dis 136:556-560, 1987.
47. Mifflin TE, J Bowden, MA Lovell, DE Bruns, FG Hayden, DHM Groschell and J Savory. Comparison ofradioactive (
32P and
35S) and biotinylated probes for detection of cytomegalovirus DNA. Clin Biochem
20:231-235, 1987.
48. Hayden FG, SE Mills, DJ Innes, A Darragh, M Just and SN Linder-Chiccolunghi. Tolerance and nasalhistopathological effects of long-term, low-dose recombinant interferon alfa-2A (Roferon-A). Antiviral Res8:139-149, 1987.
49. VanLandingham KE, HB Barsteller, GW Ross and FG Hayden. Relapse of herpes simplex virusencephalitis after conventional acyclovir therapy. J Amer Med Assoc 259:1051-1053, 1988.
50. Gaffey JM, DL Kaiser and FG Hayden. Ineffectiveness of oral terfenadine in natural colds: evidence against histamine as a mediator of common cold symptoms. Pediatr Infect Dis 7:215-242, 1988.
Bibliography
6
51. Stokes CE, JM Bernstein, SA Kyger and FG Hayden. Rapid diagnosis of influenza A and B by 24hfluorescent focus assays. J Clin Microbiol 26:1263-1266, 1988.
52. Herold DA, PK Anonick, M Kinter and FG Hayden. Measurement of rimantadine in plasma by capillarygas chromatography/mass spectrometry with a deuterium-labeled internal standard. Clin Chemistr 34:1597-1599, 1988.
53. Sperber SJ, PA Levine, DJ Innes, SE Mills and FG Hayden. Tolerance and efficacy of recombinantinterferon-betaserine in healthy adults. J Infect Dis 158:166-175, 1988.
54. Gaffey MJ, FG Hayden, JC Boyd and JM Gwaltney Jr. Ipratropium bromide treatment of experimentalrhinovirus infection. Antimicrob Agents Chemother 32:1644-1647, 1988.
55. Hayden FG, JM Gwaltney Jr and RJ Colonno. Modification of experimental rhinovirus colds by receptorblockage. Antiviral Res 9:233-247, 1988.
56. Tominack RL, RJ Wills, LE Gustavson and FG Hayden. Multiple-dose pharmacokinetics of rimantadinein elderly adults. Antimicrob Agents Chemother 32:1813-1819, 1988.
57. Hayden FG, DJ Innes, SE Mills and PA Levine. Intranasal tolerance and histopathologic effects of a novelsynthetic interferon, rIFN- Con1. Antiviral Res 10:225-234, 1988.
58. Whitley RJ, Corey L, Arvin A, Lakeman FD, Sumaya CV, Wright PF, Dunkle LM, Steele RW, SoongSJ, Nahmias AJ, Alford CA, Powell DA, Joaquin VS, and the NIAID Collaborative Antiviral StudyGroup [F.G. Hayden]. Changing presentation of herpes simplex virus infection in neonates. J Infect Dis158:109-116, 1988.
59. Hayden FG, DL Kaiser and JK Albrecht. Intranasal interferon alfa-2b treatment of naturally occurringcommon colds. Antimicrob Agents Chemother 32:224-230, 1988.
60. Sperber SJ, JV Sorrentino, DK Riker and FG Hayden. Evaluation of an alpha agonist alone and incombination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds.Bull N Y Acad Med 65:145-160, 1989.
61. Hsia J, GL Simon, N Higgins, AL Goldstein and FG Hayden. Immune modulation by aspirin duringexperimental rhinovirus colds. Bull N Y Acad Med 65:45-56, 1989.
62. Sperber SJ and FG Hayden. Comparative susceptibility of respiratory viruses to recombinant alfa-2 andbeta interferon. J Interferon Res 9:285-293, 1989.
63. McBride TP, WJ Doyle, FG Hayden and JM Gwaltney, Jr. Alteration of eustachian tube, middle ear andnose in rhinovirus infection. Arch. Otolaryn-Head and Neck Surg 115:1054-1059, 1989.
64. Sperber SJ, PA Levine, JV Sorrentino, DK Riker and FG Hayden. Ineffectiveness of recombinantinterferon-betaserine nasal drops for prophylaxis of natural colds. J Infect Dis 160:700-705, 1989.
65. Whitley RJ, CG Cobbs, CA Alford, SJ Soong, MS Hirsch, JD Connor, L Corey, DF Hanley, M Levin,DA Powell, and the NIAID Collaborative Antiviral Study Group, [FG Hayden]. Diseases that mimicherpes simplex encephalitis: diagnosis, preventation, and outcome. J Amer Med Assoc 262:234-239,1989.
66. Hsia J, MB Sztein, PH Naylor, GL Simon, AL Goldstein and FG Hayden. Modulation of thymosin1 andthymosin ß4 levels and peripheral blood mononuclear cell subsets during experimental rhinovirus colds.Lymphokine Res 8:383-391, 1989.
Bibliography
7
67. Sperber SJ and Hayden FG. Protective effect of rhinovirus receptor blocking antibody in human fibroblastcells. Antiviral Res 12:231-238, 1989.
68. Hayden FG, RB Belshe, RD Clover, AJ Hay, MG Oakes, and W Soo. Emergence and apparenttransmission of rimantadine-resistant influenza A virus in families. N Engl J Med 321:1696-1702, 1989.
69. Hayden FG, BR Rollins, and AJ Hay. Anti-influenza virus activity of the compound LY253963.Antiviral Res 14:25-38, 1990.
70. Hsia J, AL Goldstein, GL Simon, M Sztein, and FG Hayden. Interleukin-2 and interferon-production, NKactivity and antigen-stimulated blastogenesis during experimental rhinovirus colds. J Infect Dis 162:591-597, 1990.
71. Farr BM, JM Gwaltney, Jr., JO Hendley, FG Hayden, RM Naclerio, T McBride, WJ Doyle, JVSorrentino, and D Proud. A randomized controlled trial of glucocorticoid prophylaxis against experimentalrhinovirus infection. J Infect Dis 162:1173-77, 1990.
72. Crump CE, BS Rollins, and FG Hayden. In vitro antiviral activity and cytotoxicity of aspirin: Lack ofselective activity against influenza A virus or rhinovirus. Antiviral Chemistry and Chemotherapy 1:217-221, 1990.
73. Soong S, NE Watson, GR Caddell, CA Alford, RJ Whitley, and the NIAID Collaborative Antiviral StudyGroup [FG Hayden]. Use of brain biopsy for diagnostic evaluation of patients with suspected herpessimplex encephalitis: A statistical model and its clinical implications. J Infect Dis 163:17-22, 1991.
74. Whitley R, A Arvin, C Prober, L Corey, S Burchett, S Plotkin, S Starr, R Jacobs, D Powell, A Nahmias,C Sumaya, K Edwards, C Alford, G Caddell, S Soong, and the NIAID Collaborative AntiviralStudy Group [FG Hayden]. Predictors of morbidity in neonates with herpes simplex virus infections. NEngl J Med 324:450-454, 1991.
75. Whitley R, A Arvin, C Crober, S Burchett, L Corey, D Powell, S Plotkin, S Starr, C Alford, J Connor,R Jacobs, A Nahmias, S Soong, and the NIAID Collaborative Antiviral Study Group [FG Hayden]. Acontrolled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. N Engl JMed 324:444-449, 1991.
76. Arruda E, FG Hayden, JF McAuliffe, MA de Sousa, SB Mota, MI McAuliffe, FC Geist, Carvalho, MCFernandes, RL Guerrant, and JM Gwaltney, Jr. Acute Respiratory viral illness in ambulatory children ofurban northeast Brazil: Importance of rhinovirus. J Infect Dis 164:252-58, 1991.
77. Arruda E, TE Mifflin, JM Gwaltney, Jr, B Winther, and FG Hayden. Localization of rhinovirusreplication in vitro with in situ hybridization. J Med Virol 34:38-44, 1991
78. Sweet C, FG Hayden, KJ Jakeman, S Grambas, and AJ Hay. Virulence of rimantadine-resistant humaninfluenza A (H3N2) viruses in ferrets. J Infect Dis 164:969-72, 1991.
79. Hayden FG, SJ Sperber, RB Belshe, RD Clover, AJ Hay, and S Pyke. Recovery of drug-resistantinfluenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 35:1741-47, 1991.
80. Hechemy KE, JA Fox, DHM Groschel, FG Hayden, and RP Wenzel. Immunoblot studies to analyzeantibody to the Rickettsia typhi group antigen in sera from patients with acute febrile cerebrovasculitis. JClin Microbiol 29:2559-2565, 1991.
81. Whitley RJ, JW Gnann Jr, D Hinthorn, C Liu, R Pollard, F Hayden, G Mertz, M Oxman, SJ Soong, andthe NIAID Collaborative Antiviral Study Group [FG Hayden]. Disseminated herpes zoster in theimmunocompromised host: A comparative trial of acyclovir and vidarabine. J Infect Dis 165:450-5, 1992.
Bibliography
8
82. Sperber SJ, BV Smith, and FG Hayden. Serologic response and tolerability to booster immunization ofhealthy seropositive adults with live or inactivated varicella vaccine. Antiviral Res 17:213-222, 1992.
83. Hayden FG, K Andries, and PAJ Janssen. Safety and efficacy of intranasal pirodavir (R77975) inexperimental rhinovirus infection. Antimicrob Agents Chemother 36:727-32, 1992.
84. Gwaltney JM, O Hendley, FG Hayden, K McIntosh, FB Hollinger, JL Melnick, and RB Turner. Updatedrecommendations for safety-testing of viral inocula used in volunteer experiments on rhinovirus colds. Prog Med Virol 39;256-63, 1992.
85. Arruda E, CE Crump, SD Marlin, VJ Merluzzi, and FG Hayden. In vitro studies of the antirhinovirusactivity of soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother 36:1186-91, 1992.
86. Sperber SJ, JO Hendley, FG Hayden, DK Riker, JV Sorrentino, and JM Gwaltney, Jr. Effects of naproxenin experimental rhinovirus colds. Ann Intern Med 117:37-41, 1992.
87. Balfour, HH, HA Rotbart, S Feldman, LM Dunkle, HM Feder, CG Prober, GF Hayden, S Steinberg, RJWhitley, L Goldberg, MP McGuirt and the Collaborative Acyclovir Varicella Study Group [FG Hayden]. Acyclovir treatment of varicella in otherwise healthy adolescents. J Pediatr 120:627-33, 1992.
88. Winther B, DJ Innes, J Bratsch, and FG Hayden. Lymphocyte subsets in the nasal mucosa and peripheralblood during experimental rhinovirus infection. American J Rhinol 6:149-56, 1992.
89. Sperber, SJ, WJ Doyle, TP McBride, JV Sorrentino, DK Riker, JM Gwaltney, Jr., and FG Hayden. Otologic effects of intranasal interferon-ßserine treatment of experimental rhinovirus colds. ArchOtolarnygol - Head and Neck Surgery 118:933-36, 1992.
90. Turner BW, WS Cail, JO Hendley, FG Hayden, WJ Doyle, JV Sorrentino, and JM Gwaltney, Jr.Physiologic abnormalities in the paranasal sinuses during experimental rhinovirus colds. J Allergy ClinImmunol 90:474-8, 1992.
91. Parekh, HH, KT Cragun, FG Hayden, JO Hendley, and JM Gwaltney, Jr. Nasal mucus weights inexperimental rhinovirus infection. American J Rhinol 6:107-10, 1992.
92. Stone AA, DH Bovbjerg, JM Neale, A Napoli, H Valdimarsdottir, D Cox, FG Hayden, and JM Gwaltney,Jr. Development of common cold symptoms following experimental rhinovirus infection is related to priorstressful life events. Behavioral Medicine 18:115-120, 1992.
93. Turner RB, FJ Dutko, NH Goldstein, G Lockwood, and FG Hayden. Efficacy of oral WIN 54954 forprophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother 37:297-300, 1993.
94. Jernigan JA, BS Lowry, FG Hayden, SA Kyger, BP Conway, DHM Groschel, and BM Farr. Adenovirustype 8 epidemic keratoconjunctivitis in an eye clinic: Risk factors and control. J Infect Dis 167:1307-13,1993.
95. Rollins BS, AHA Elkatieb, and FG Hayden. Comparative anti-influenza virus activity of 2'-deoxy2'-fluororibosides in vitro. Antiviral Res 21:357-68, 1993.
96. Elkhatieb AA, G Hipskind, D Woerner, and FG Hayden. Middle ear abnormalities during naturalrhinovirus colds in adults. J Infect Dis 168:618-21, 1993.
97. Duff AL, ES Pomeranz, LE Gelber, GW Price, H Farris, FG Hayden, TAE Platts-Mills, and PWHeymann. Risk factors for acute wheezing in infants and children: Viruses, passive smoke, and IgEantibodies to inhalant allergens. Pediatrics 92:535-40, 1993.
Bibliography
9
98. Crump, CE, E Arruda, and FG Hayden. In vitro inhibitory activity of sICAM-1 for the numberedserotypes of human rhinovirus. Antiviral Chem Chemother 4:323-27, 1993.
99. Arruda E and FG Hayden. Detection of human rhinovirus RNA in nasal washings by PCR. MolecularCellular Probes 7:373-79, 1993.
100. Doyle, WJ, DK Riker, TP McBride, FG Hayden, JO Hendley, JD Swarts, TJ Witek, Jr., JV Sorrentino,and JM Gwaltney, Jr. Therapeutic effects of an anti-cholinergic/sympathomimetic combination in inducedrhinovirus colds. Ann Otol Rhinol Laryngol 102:521-27, 1993.
101. Arruda, E, CE Crump, and FG Hayden. In vitro selection of human rhinovirus relatively resistant tosoluble intercellular adhesion molecule-1. Antimicrob Agents Chemother 38:66-70, 1994.
102. Doyle WJ, DP Skoner, FG Hayden, CA Buchman, JT Seroky, and P Fireman. Nasal and otologic effectsof experimental influenza A virus infection. Ann Otol Rhinol Laryngol 103:59-69, 1994.
103. Hayden, FG, AR Tunkel, JJ Treanor, RF Betts, S Allerheiligen, and J Harris. Oral LY 217896 forprevention of experimental influenza A virus infection and illness in humans. Antimicrob AgentsChemother 38:1178-81, 1994.
104. Crump CE, E Arruda, and F Hayden. Comparative anti-rhinoviral activity of soluble intercellular adhesionmolecule-a (sICAM-1) and chimeric ICAM-1/IgA molecule. Antimicrob Agents Chemother 38:1425-27,1994.
105. Hayden FG, BS Rollins, and LK Madren. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 25:123-31, 1994.
106. Hayden FG, GJ Hipskind, DH Woerner, GF Eisen, M Janssens, PAJ Janssen, and K Andries. Intranasalpirodavir (R77,975) treatment of rhinovirus colds. Antimicrob Agents Chemother 39:290-94, 1995.
107. Madren LK, C Shipman, Jr., and FG Hayden. In vitro inhibitory effects of combinations of anti-influenzaagents. Antiviral Chemistry and Chemotherapy 6:109-13, 1995.
108. Arruda E, TR Boyle, B Winther, DC Pevear, JM Gwaltney, Jr., and FG Hayden. Localization of humanrhinovirus in the upper respiratory tract by in situ hybridization. J Infect Dis 171:1329-33, 1995.
109. Buchman CA, JD Swarts, JT Seroky, N Panagiotou, F Hayden, and WJ Doyle. Otologic and systemicmanifestations of experimental influenza A virus infection in the ferret. Otolaryngol Head Neck Surg112:572-8, 1995.
110. Rao, SS, JO Hendley, FG Hayden, and JM Gwaltney, Jr. Symptom expression in natural andexperimental rhinovirus colds. Amer J Rhinol 9:49-52, 1995.
111. Kuter, BJ, A Ngai, CM Patterson, BO Staehle, I Cho, H Matthews, PJ Provost, CJ White, and theOka/Merck Varicella Vaccine Study Group [FG Hayden]. Safety, tolerability, and immunogenicity of tworegimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Vaccine 13:967-72,1995.
112. Klimov AI, E Rocha, FG Hayden, PA Shult, LF Roumillat, and NJ Cox. Prolonged shedding ofamantadine-resistant influenza A viruses by immunodeficient patients: detection by PCR-restrictionanalysis. J Infect Dis 172:1352-5, 1995.
113. Buchman CA, WJ Doyle, DP Skoner, C Post, CM Alper, JT Seroky, K Anderson, RA Preston, FGHayden, P Fireman, and GD Ehrlich. Influenza A virus-induced acute otitis media. J Infect Dis 172:1348-
Bibliography
10
51, 1995.
114. Hayden FG, JJ Treanor, RF Betts, M Lobo, JD Esinhart, and EK Hussey. Safety and efficacy of theneuraminidase inhibitor GG167 in experimental human influenza. J Amer Med Assoc 275:295-299, 1996.
115. Hayden FG, CA Sable, JD Connor, and J Lane. Intravenous ribavirin by constant infusion for seriousinfluenza and parainfluenzavirus infection. Antiviral Therapy 1:51-56, 1996.
116. Blumberg EA, C Albano, T Pruett, R Isaacs, J Fitzpatrick, J Bergin, C Crump, and FG Hayden. Theimmunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 22:295-302, 1996.
117. Doyle WJ, DP Skoner, Y Igarashi, F Hayden, AP Kaplan, MA Kaliner, and P Fireman. Pattern of nasalsecretions using experimental influenza virus infection. Rhinology 34:2-8, 1996.
118. Adal KA, RH Flowers, AM Anglim, FG Hayden, MG Titus, BJ Coyner, and BM Farr. Prevention ofnosocomial influenza. Infect Contl Hosp Epidemiol 17:641-648, 1996.
119. Hayden FG, L Diamond, PB Wood, DC Korts, and MT Wecker. Effectiveness and safety of intranasalipratropium bromide in common colds. Ann Intern Med 125:89-97, 1996.
120. Whitley RJ, H Weiss, JW Gnann, Jr., S Tyring, L Sherrill, R Pollard, GJ Mertz, PG Pappas, CJSchleupner, F Hayden, J Wolfe, S-J Soong, and the National Institute of Allergy and Infectious Diseasesand Collaborative Antiviral Study Group. Acyclovir with and without prednisone for the treatment ofherpes zoster: A randomized, placebo-controlled trial. Ann Intern Med 125:376-83, 1996.
121. Arruda E, CE Crump, BS Rollins, A Ohlin, and FG Hayden. Comparative susceptibility of humanembryonic fibroblasts and HeLa cells for isolation of human rhinoviruses. J Clin Microbiol 34:1277-79,1996.
122. Gustafson LM, D Proud, JO Hendley, FG Hayden, and JM Gwaltney, Jr. Oral prednisone therapy inexperimental rhinovirus infections. J Allergy Clin Immunol 97:1009-14, 1996.
123. Turner JC, Hayden FG, Lobo MC, Ramirez CE, and Murren D. Epidemiologic evidence for LancefieldGroup C Beta-Hemolytic Streptococci as a cause of exudative pharyngitis in college students. J ClinMicrob 35:1-4, 1997.
124. Pitkäranta A, Arruda E, Malmberg H, and Hayden FG. Detection of rhinovirus in sinus brushings ofpatients with acute community-acquired sinusitis by reverse transcription-PCR. J Clin Microb 35:1791-93, 1997.
125. Hayden FG, Osterhaus A, Treanor JJ, Fleming DM, Aoki FY, Nicholson G, Bohnen AM, Hirst HM,Keene O, and Wightman K for the GG167 Influenza Study Group. Efficacy and safety of the neuraminidaseinhibitor zanamivir (GG167) in the treatment of influenza virus infections. New Engl J Med 337(13):874-9, 1997.
126. Walker JB, Hussey EK, and Hayden FG. Effects of the neuraminidase inhibitor zanamivir on otologicmanifestations of experimental human influenza. J Infect Dis 176:1417-22, 1997.
127. Arruda E, Pitkäranta A, Witek TJ, Doyle CA, and Hayden FG. Frequency and natural history ofrhinovirus infections in adults during autumn. J Clin Microb 35:2864-68, 1997.
128. Hayden FG, Fritz RS, Lobo MC, Alvord WG, Strober W, and Straus SE. Local and systemic cytokineresponses during experimental human influenza A virus infection: Relation to symptom formation and hostdefense. J Clin Invest 101:643-649, 1998.
Bibliography
11
129. Doyle WJ, Skoner DP, Patel A, and Hayden FG. Effect of rimantadine on induced specific serumhaemagglutination-inhibiting antibody and nasal IgA titres after experimental exposure of adults toinfluenza A virus. Antiviral Therapy 3:19-23, 1998.
130. Belshe RBN, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG,Kotloff K, Zangwill K, Iacuzio D, Wolff M, Reisinger K, Block SL, Wittes J, and Rabinovich R.Efficacy of trivalent live attenuated intranasal influenza vaccine in children. N Eng J Med 338:1405-1412,1998.
132. Pitkaranta A, Hayden FG, Korts D, and Wecker M. Combined intranasal ipratropium bromide andoxymetazoline in experimental rhinovirus infection. Am J Rhinology 12:125-129, 1998.
133. Pitkaranta A, Virolainen A, Hero J, Arruda E, and Hayden FG. Detection of rhinovirus, respiratorysyncytial virus and coronavirus infections in acute otitis media by reverse transcriptase-polymerase chainreaction. Pediatr 102:291-295, 1998.
134. Stilianakis NI, Perelson AS, and Hayden FG. Emergence of drug resistance during an influenza epidemic:Insights from a mathematical model. J Infect Dis 177:863-73, 1998.
135. Doyle WJ, Skoner DP, Alper CM, Allen G, Moody SA, Seroky JT, and Hayden FG. Effect ofrimantadine treatment on clinicl manifestations on otological complications in adults experimentallyinfected with influenza A (H1N1) virus. J Infect Dis 177:1260-5, 1998.
136. Bertino JS Jr., Thoelen S, VanDamme P, Bryan JP, Becherer PR, Frey S, Hayden FG, Marcus LC,Parenti DM, Sperling M, Chan ISF, Brown L, and Nalin D. A dose response study of hepatitis A vaccinein healthy adults who are ∃30 years old and weigh ∃77 kg. J Infect Dis 178:1181-4, 1998.
137. Blumberg, EA, Fitzpatrick J, Stutman PC, Hayden FG, and Brozena SC. Safety of influenza vaccine inheart transplant recipients. Journal of Heart and Lung Transplantation. 17:1075-80, 1998.
138. Pitkaranta A, Jero J, Arruda E, Virolainen A and Hayden FG. Polymerase chain reaction-based detection ofrhinovirus, respiratory syncytial virus and coronavirus in otitis media with effusion. J Pediatr 133:390-4,1998.
139. Gentile DA, Whiteside T, Fireman P, Hayden FG, Doyle W, and Skoner DP. Increased interleukin-6levels in nasal lavages following experimental influenza A viral infection. Clin Diagn Lab Immunol 5:604-608, 1998.
140. Murphy AW, Platts-Mills TAE, Lobo M, and Hayden F. Respiratory nitric oxide levels in experimentalhuman influenza. Chest 114(2):452-56, 1998.
141. Rotbart HA, Brennan PJ, Fife KH, Romero JR, Griffin JA, McKinlay MA, and Hayden FG. Enterovirusmeningitis in adults. CID 27:896-8, 1998
142. Hayden FG, Atmar RL, Schilling M, Johnson C, Poretz D, Paar D, Huson L, Ward P, Mills RG. Use ofthe selective oral neuraminidase inhibitor oseltamivir to prevent influenza. N Engl J Med 341:1336-43,1999.
143. Turner RB, Wecker MT, Pohl G, Witek RJ, McNally E, St.George R, Winther B, and Hayden FG.Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection. JAmer Med Assoc 281:1797, 1999.
144. Fritz RS, Hayden FG, Calfee DP, Cass LMR, Peng AW, Alvord WG, Strober W, and Straus SE. Nasalcytokine and chemokine responses in experimental influenza A virus infection: results of a placebo-
Bibliography
12
controlled trial of intravenous zanamivir treatment. J Infect Dis 180:586-93, 1999.
145. Hayden FG, Treanor JJ, Fritz RS, Lobo M, Betts RF, Miller M, Kinnersley N, Mills RG, Ward P, andStraus SE. Use of oral neuraminidase inhibitor oseltamivir in experimental human influenza. J Amer MedAssoc 282:1240-1241, 1999.
146. Calfee DP, Peng AW, Hussey EK, Lobo M, and Hayden FG. Safety and efficacy of once daily intranasalzanamivir in preventing experimental human influenza A infection. Antiviral Therapy 4:143-149, 1999.
147. Rakes GP, Aruda E, Ingram JM, Hoover GE, Zanbrano JC, Hayden FG, Platts-Mills TAE, Heymann PW. Rhinivorus and respiratory syncytial virus in wheezing children requiring emergency care. Amer J RespCrit Care Med 159:785-90, 1999.
148. Treanor JJ, Hayden FG, Vrooman PS, Barbarash RB, Bettis R, Riff D, Singh S, Kinnersley N, Ward P,and Mills RG. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acuteinfluenza. J Amer Med Assoc 283:1016-24, 2000.
149. Belshe RB, Cruber WC, Mendelman PM, Cho I, Reisinger K, Block SL, Wittes J, Iacuzio D, Piedra P,Treanor J, King J, Kotloff K, Bernstein DI, Hayden FG, Zangwill K, Yan L, and Wolff M. Efficacy ofvaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant(A/Sydney) not contained in the vaccine. J Pediatr 136:168-175, 2000.
150. Kaiser L, Henry D, Flack NP, Keene O, and Hayden FG. Short-term treatment with zanamivir to preventinfluenza: results of a placebo-controlled study. Clin Infect Dis 30:587-9, 2000.
151. Belshe RB, Gruber WC, Mendelman PM, Mehta HB, Mahmood K, Reisinger K, Treanor J, Zangwill K,Hayden FG, Bernstein DI, Kotloff K, King J, Piedra PA, Block SL, Yan L, and Wolff M. Correlates ofimmune protection induced by live atenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. JInfect Dis 181:1133-7, 2000.
152. Hayden FG, Jennings L, Robson R, Schiff G, Jackson H, Rana B, McClelland G, Ipe D, Roberts N, andWard P. Oral oseltamivir in human experimental influenza B infection. Antiviral Therapy 5:205-13, 2000.
153. Kaiser L, Keene ON, Hammond J, Elliott M, and Hayden FG. Impact of zanamivir on antibiotics use forrespiratory events following acute influenza in adolescents and adults. Arch Int Med 160:3234-3240, 2000.
154. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliott MJ, Hammond JM, Sharp SJ and Ossi MJ.Inhaled zanamivir for preventing influenza in families. N Engl J Med 343:1282-89, 2000.
155. Kaiser L, Crump CE, and Hayden FG. In vitro activity of pleconaril and AG7-88 against selectedserotypes and clinical isolates of human rhinovirus. Antiviral Res 47:215-220, 2000.
156. Gubareva LV, Kaiser L, Matrosovich M, Soo-Hoo Y, and Hayden FG. Selection of influenza virusmutants in experimentally infected volunteers treated with oseltamivir. J Infect Dis 183:523-531, 2001.
157. Whitley RJ, Hayden FG, Reisinger KS, Young N, Dutkowski R, Ipe D, Mills RG, and Ward P. Oraloseltamivir treatment of influenza in children. Pediatr Infect Dis J 20:127-33, 2001.
158. Gubareva LV, Webster RG, Hayden FG. Detection of influenza virus resistance to neuraminidaseinhibitors. Antiviral Research. Antiviral Res. 53:47-61, 2002.
159. Gubareva LV, Webster RG, Hayden FG. Comparison of the activity of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants.Antimicrob Agents and Chemother 45:3403-8, 2001.
Bibliography
13
160. Hayden FG. Perspectives on antiviral use during pandemic influenza. The Royal Society, Phil. Trans. R.Soc. Lond. B 356:1877-1884, 2001.
161. Winther B, Arruda E, Witek TJ, Marlin SD, Tsianco MM, Innes DJ, Hayden FG. Expression of ICAM-1in nasal epithelium and levels of soluble ICAM-1 in nasal lavage fluid during human experimentalrhinovirus infection.. Archives of Otalaryngology-Head & Neck Surgery (in press).
162. Winther B, Hayden FG, Arruda E, Dutkowski R, Ward P, Hendley JO. Viral respiratory infection inschool children: effects on middle ear pressure. Pediatrics (in press).
Bibliography
14
Books
1. Richmond DD, Whitley RJ, Hayden F G, (eds). Clinical Virology, Churchill Livingstone, 1997.
Chapters
1. Hayden FG and RG Douglas Jr. Antiviral Agents. In: GL Mandell, RG Douglas Jr, and JE Bennett (ed.),Principles and Practices of Infectious Diseases. John Wiley & Sons, New York, 1979, pp. 353-369.
2. Gwaltney JM Jr and FG Hayden. The nose and infection. In: D Proctor and I Andersen (eds.), The Nose:Upper Airway Physiology and Atmospheric Environment. Elsevier Biomedical Press, Amsterdam, 1982,pp. 399-422.
3. Hayden FG. Antiviral Chemotherapy. In: LE Cluff and JE Johnson III (eds.), Clinical Concepts ofInfectious Diseases, 3rd edition. Williams & Williams Co., Baltimore, 1982, pp 290-297.
4. Hayden FG. Coronaviruses. In: JH Stein (ed.), Internal Medicine, Little Brown and Co., Boston, 1983, pp1272-1273.
5. Hayden FG and SA Halperin. Paramyxoviruses. Ibid. pp 1265-1272.
6. Magnussen CR, FG Hayden, and WM Valenti. Laboratory aids. In: RE Resse and RG Douglas Jr (ed.), APractical Approach to Infectious Diseases. Little Brown and Co., Boston, 1983, pp 19-49.
7. Hayden FG and RG Douglas Jr. Antiviral agents. In: GL Mandell, RG Douglas Jr, and FE Bennett (eds.),Principles and Practices of Infectious Diseases. 2nd Ed., John Wiley and Sons, New York, 1985, pp 270-286.
8. Hayden FG. Herpes simplex virus infections. In: RF Edlich and DA Spyker (eds.), Current EmergencyTherapy - 1985. Aspen Systems Corp., Rockville, 1985, pp 488-492.
9. Hayden FG. Clinical applications of antiviral agents for chemoprophylaxis and therapy of respiratory viralinfections. In: A Billiau, E deClercq, and H Schellekens (eds.), Antiviral Research, Supplement 1. ElsevierScience Publishers B.V., Amsterdam, 1985, pp 229-239.
10. Hayden FG, OL Laskin, and RG Douglas Jr. Chapter 11. Susceptibility testing of viruses andpharmacodynamics of antiviral agents. In: V Lorian (ed.), Antibiotics in Laboratory Medicine. 2nd Ed.Williams and Wilkins, Baltimore, 1986, pp 359-380.
11. Hayden FG. Animal models in influenza for evaluation of antiviral agents. In: O Zak and M Sande (eds.),Animal Models in the Evaluation of Chemotherapy. Academic Press, Inc., London, 1986, pp 353-371.
12. Hayden FG. Use of interferons for prevention and treatment of respiratory viral infections. In: J Mills andL Corey (eds.), Antiviral Chemotherapy: New Directions for Clinical Application and Research. ElsevierScientific Publishing Co., Inc., New York, 1986, pp 28-39.
13. Hayden FG. Combinations of antiviral agents for treatment of influenza virus infections. In Oxford JS,Field HJ, and Reeves DS (eds). Drug Resistance in Viruses, Other Microbes, and Eukaryotes, AcademicPress, London, 1986, pp 177-183.
14. Hayden FG and MJ Gaffey. Paramyxovirus infections (parainfluenza, mumps, measles, respiratorysyncytial virus). Chapter 235 In: JH Stein (ed.), Internal Medicine. 2nd Edition, Little Brown and Co.,Boston, 1987, pp 1578-1586.
Bibliography
15
15. Hayden FG and MJ Gaffey. Coronavirus infections. Chapter 236 In: JH Stein (ed.) Internal Medicine. 2ndEdition, Little Brown and Co., Boston, 1987, pp 1586-1591.
16. Tominack RL and FG Hayden. Rimantadine hydrochloride and amantadine hydrochloride use in influenzaA virus infections. In: V Knight (ed.), Antiviral Chemotherapy, Infectious Disease Clinics of NorthAmerica, WB Saunders, Co., Philadelphia, 1:459-478, 1987.
17. Sperber SJ and FG Hayden. Antiviral chemotherapy and prophylaxis of viral respiratory disease. In: WLDrew (ed.), Clinics in Laboratory Medicine, WB Saunders, Philadelphia, 7:869-896, 1987.
18. Hayden FG and JM Gwaltney Jr. Viral infections. In: LF Murray and JA Nadell (eds.), Textbook ofRespiratory Medicine, WB Saunders, Philadelphia, 1988, pp 748-802.
19. Hayden FG. Intranasal interferons for control of respiratory viral infections. In: M Revel (ed.), ClinicalAspects of Interferon, Kluwer Academic Publishers, Boston, 1988, pp 3-16.
20. Sperber SJ and FG Hayden. Perspectives in the use of antiviral agents for the prevention and treatment ofrespiratory viral infections. In: E DeClercq (ed.), Clinical Use of Antiviral Drugs, Martinus NijhoffPublishing, Boston, 1988, pp 317-340.
21. Hayden FG and RG Douglas Jr. Antiviral agents. Chapter 34. In: GL Mandell, RG Douglas Jr, and JEBennett (eds.), Principles and Practices of Infectious Diseases. 3rd Edition. Churchill Livingston, Inc.,New York, 1989, pp 370-393.
22. Hayden FG. Interferons. Chapter 35. In: GL Mandell, RG Douglas Jr, and JE Bennett (eds.), Principlesand Practices of Infectious Diseases. 3rd Edition. Churchill Livingston, Inc., New York, 1989, pp 393-398.
23. Hayden FG. Update on antiviral chemotherapy of respiratory viral infections. In: L Corey and J Mills(eds.), Antiviral Chemotherapy: New Directions for Clinical Application and Research, Vol . 2 . ElsevierScientific Publishing Co., Inc., New York, 1989, pp 117-142.
24. Gaffey MJ and FG Hayden. Paramyxovirus and coronavirus infection. Chapter 185. In: JH Stein, (eds.), Internal Medicine, 3rd Edition, Little Brown and Co., Boston, 1989, pp 1371-79.
25. Hayden FG and Hay AJ. Emergence and transmission of drug-resistant influenza A viruses. In: JJ Holland(ed.) Current Topics in Microbiology and Immunology, Vol 176: Genetic Diversity of RNA Viruses.Springer-Verlag, Berlin, 1992, pp 119-129.
26. Arruda E and FG Hayden. Rhinoviruses. In: J Lederberg (ed.), Encyclopedia of Microbiology. Vol 3,Academic Press, Orlando, Florida, 1992, pp. 555-64.
27. Hayden FG and RB Couch. Clinical and epidemiological importance of influenza A viruses resistant toamantadine and rimantadine. In: C Hannoun, Kendal AP, Klenk HD, and Ruben FL (eds.), Options forthe Control of Influenza II. Elsevier Science Publishers, Amsterdam, The Netherlands, 1993, pp. 333-42.
28. Hayden FG. Update on treatment of respiratory viral infections. In: J Mills and L Corey (eds.) AntiviralChemotherapy: New Directions for Clinical Application and Research, Vol. 3. PTR Prentice Hall, NewJersey, 1993, pp. 207-228.
29. Arruda E and FG Hayden. Role of cytokines in viral infections. In: A Gearing, J Rossio, JJ Oppenheim(eds.) Clinical Applications of Cytokines: Role in Pathogenesis, Diagnosis and Therapy. OxfordUniversity Press, Oxford, 1993, pp. 79-92.
30. Hayden FG and GF Hayden. Paramyxovirus (Measles, Parainfluenza, Mumps, and Respiratory Syncytial
Bibliography
16
Virus), Rubella Virus, and Cornonavirus Infections, Chapter 246. In: JH Stein (ed.) Internal Medicine,Fourth Edition, Mosby-Year Book, Inc., St. Louis, 1994, pp. 2000-12.
31. Arruda E and FG Hayden. Clinical studies of antiviral agents for picornaviral infections.Chapter 12. In: DJ Jeffries and E de Clercq (eds.) Antiviral Chemotherapy. John Wiley & Sons,Chichester, UK, 1995, pp. 321-55.
32. Hayden FG and JM Gwaltney, Jr. Viral Infections, Chapter 33. In: JF Murray and JA Nadell (eds). Textbook of Respiratory Medicine, Second Edition, WB Saunders, Philadelphia, PA, 1994, pp 977-1035.
33. Hayden FG. Antiviral agents. Chapter 32. In: GL Mandell, JE Bennett, and R. Dolin (eds.), Principles andPractices of Infectious Diseases. 4th Edition. Churchill Livingston, Inc., New York, NY, 1995, pp 411-450.
34. Sable CA and FG Hayden. Orthomyxoviral and paramyxoviral infections in transplant patients. In: RRubin (ed.) Infectious Disease Clinics of North America: Infection in Transplantation, WB Saunders,Philadelphia, PA, 1995, pp 987-1003.
35. Hayden FG. Antiviral agents, Chapter 50. In: JG Hartman and LE Limbird (eds.), Goodman andGilman's The Pharmacologic Basis of Therapeutics, Ninth Edition, McGraw Hill, New York, NY, 1996,pp 1191-1223.
36. Arruda E, FC Geist, MI McAuliffe, and FG Hayden. Viral respiratory tract illnesses in developingtropical area: prospective studies in Goncalves Dias, Fortaleza, Brazil. Chapter 11. In: RL Guerrant, MAde Souza, MK Nations (eds.) At the Edge of Development: Health Crisis in a Transitional Society. Carolina Academic Press, 1996, pp 203-223.
37. Hayden FG. Influenza, Chapter 332. In: JC Bennett and F Plum (eds.) Cecil Textbook of Medicine,20th Edition, WB Saunders Company, Philadelphia, PA 1996, pp 1753-57.
38. Hayden FG. Amantadine and rimantadine resistance in influenza viruses, Chapter 4. In: D Richman (ed.),Antiviral Drug Resistance. J Wiley and Sons, Inc., Chichester, UK 1996, pp 59-77.
39. Arruda E and FG Hayden. Update on therapy of influenza and rhinovirus infections. In: J Mills, PAVolberding, and L Corey (eds.). Antiviral Chemotherapy 4: New Directions for Clinical Application andResearch, Advances in Experimental Medicine and Biology 314:175-87, Plenum Press, New York, 1996.
40. Hayden FG, Lobo M, Hussey EK, and Eason CU. Efficacy of intranasal GG167 in experimental humaninfluenza A and B virus infection. In: LE Brown, AW Hampson and RG Webster (eds.). Options for thecontrol of influenza III, Elsevier Science B.V., Amsterdam, The Netherlands, 1996, pp 718-25.
41. Hayden FG and PA Palese. Influenza Virus. Chapter 39 In: DD Richmond, RJ Whitley, FG Hayden(eds.), Clinical Virology. Churchill Livingstone, New York, NY, 1997, pp 911-942.
42. Hayden FG and Aoki FY. Amantadine, rimantadine, and related agents. In: Yu V, Merigan T, andBarriere S (eds). Antimicrobial Therapy and Vaccines, Williams & Wilkins, Baltimore, MD, 1999, pp1344-1365.
43. Treanor JJ and Hayden FG. Experimental influenza in humans. In: Nicholson K, Webster R, and Hay A.(eds) Textbook of Influenza, Blackwell Healthcare Communications, London, UK. 1998, pp 517-537.
44. Arruda E and Hayden FG. Paramyxovirus (Parainfluenza, mumps, measles, and respiratory syncytialvirus), rubella virus, coronavirus, and adenovirus infections. Chapter 251. In: JH Stein (ed.) InternalMedicine, Fifth Edition, Mosby, Inc., St. Louis, MO, 1998, pp 1494-1505.
Bibliography
17
45. Hayden FG. Update on influenza and rhinovirus infections. In:Mills J, Volberding PA, Corey L (eds). Antiviral Chemotherapy 5 New Directions for Clinical Application and Research.Kluwer Academic/PlenumPublishers, New York, NY, 1999, pp 55-67.
46. Kaiser L, Hayden FG. Hospitalizing Influenza in Adults. In: Remington JS, Swartz MN (eds). CurrentClinical Topics in Infectious Diseases, Blackwell Science, Malden, MA, 1999, pp112-134.
47. Hayden FG. Influenza. Chapter 379. In: Goldman L, and Bennett JC (eds). Cecil Textbook of Medicine,21
st Edition, W. B. Saunders Company, Philadelphia, PA, 1999, pp 1779-1800.
48. Arruda E and Hayden FG. Influenza virus, respiratory syncytial virus, parainfluenza viruses, rhinovirus,and respiratory adenoviruses. Chapter 104. In: Guerrant RL, Walker DH, Weller PF (eds). TropicalInfectious Diseases Principles, Pathogens, & Practice, Churchill Livingstone, Philadelphia, PA, 1999, pp1109-1121.
49. Treanor JJ and Hayden FG. Viral Infections. Chapter 32. In: Murray JF, Nadel JA (eds). Textbook ofRespiratory Medicine, Third Edition, W.B. Saunders Company, Philadelphia, PA, 2000, pp. 929-984.
50. Hayden, FG. Antimicrobial agents. Chapter 50. In : Hardman JG and Limbird LE (eds). Goodman &Gilman’s The Pharmacological Basis of Therapeutics. 10
th Edition, McGraw-Hill, New York, 2001,
pp1313-1347.
Bibliography
18
Invited Reviews
1. Van Voris LP, J Bartram, and FG Hayden. Pharmacokinetics of amantadine and rimantadine.Microbiology - 1984. American Society for Microbiology, Washington, DC., pp 421-423, 1984.
2. Hayden FG. Recombinant interferon for prophylaxis and therapy of rhinovirus and influenza virusinfections. Microbiology - 1984. American Society for Microbiology, Washington, DC., pp 409-412,1984.
3. Powers RD and FG Hayden. Herpesvirus infection: Current antiviral therapy. Hospital Formulary 19:1040-1045, 1984.
4. Hayden FG, AN Schlepushkin, and NL Pushkarskaya. Combined interferon-alpha2, rimantadinehydrochloride, and ribavirin inhibition of influenza virus replication in vitro . In: RA Smith, V Knight, andJA Smith (eds.), Clinical Applications of Ribavirin. Academic Press, Orlando, pp 39-48, 1984.
5. Scheibel SF and FG Hayden. Stay alert for the serious sequelae of influenza. J Resp Dis 6:21-29, 1985.
6. Hayden FG. Recombinant interferon-alpha2 for prevention and treatment of respiratory viral infections. In:R Kono and A Nakajima (eds.), Herpes Viruses and Viral Chemotherapy. Elsevier Science PublishersB.V., Excerpta Medica, Amsterdam, pp 325-330, 1984.
7. Hayden FG. Amantadine and rimantadine: efficacy, side effects, pharmacokinetics. J Resp Dis 8(suppl11A):S45-50, 1987.
8. Sperber SJ and FG Hayden. Minireview: Chemotherapy of rhinovirus colds. Antimicrob AgentsChemother 32:409-419, 1988.
9. Hayden FG. An office guide to antiviral therapy. Emergency Med 20:155-170, 1988.
10. Sperber SJ and FG Hayden. Intranasal interferons for control of the common cold. ISI Atlas of Science:Immunol 1:20-24, 1988.
11. Doyle WJ, TP McBride, JD Swarts, FG Hayden and JM Gwaltney Jr. The response of the nasal airway,middle ear and eustachian tube to provocative rhinovirus challenge. Amer J Rhinology 2:149-154, 1988.
12. Hayden, FG. Significance of rimantadine resistance in influenza A viruses. J Res Dis 10:S62-S67, 1989.
13. Betts RF, FG Hayden, and A Monto. Safety and tolerance of a loading dose of rimantadine. J Res Dis10:S42-S45, 1989.
14. Gwaltney JM Jr, O Hendley, FG Hayden, K McIntosh, FB Hollinger, JL Melnick and RB Turner. Updated recommendations for safety-testing of viral inocula used in volunteer experiments on rhinoviruscolds. Prog Med Virol 39:256-63, 1992.
15. Hayden FG and RB Couch. Clinical and epidemiological importance of influenza A viruses resistant toamantadine and rimantadine. Rev Med Virol 2:89-96, 1992.
16. Hayden FG. Update on antiviral agents and viral drug resistance. In: G Mandell, R Douglas Jr, J Bennett(eds.), Supplements to Principles and Practice of Infectious Diseases, Vol 2, No 2. Churchill LivingstonInc., New York, 1993.
17. Hayden FG, HN Himmel, and JP Heggers. Herpesvirus infections in burn patients. Chest 106:15S-21S,1994.
Bibliography
19
18. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. Current Opinion in InfectiousDiseases 7:674-77, 1994.
19. Kimberlin CS, Crumpacker, SE Straus, KK Biron, WL Drew, FG Hayden, M McKinlay, DD Richman,and RJ Whitley. Antiviral resistance in clinical practice. Antiviral Res 26:423-38, 1995.
20. Hayden FG. Combination antiviral therapy for respiratory virus infections. Antiviral Res 29:45-48, 1996.
21. Hayden FG. Influenza in the elderly. J Geriatric Drug Therapy 10:5-23, 1996 and In: JW Cooper (ed.),Antiviral in the Elderly, Pharmaceutical Products Press, Binghamton, NY, 1996, pp 5-23.
22. Hayden FG. Combination antiviral therapy for respiratory virus infections. Antiviral Res. 29:45-48,1996.
23. Hayden FG. Antiviral agents for influenza virus infections. Pacific Basin Respiratory Virus ResearchGroup Newsletter. 4:3-6,1996.
24. Hayden, FG. Antivirals for pandemic influenza. J Infect Dis 176(Suppl 1):S56-61, 1997.
25. Hayden FG. Prevention and treatment of influenza in immunocompromised patients. Am J Med102(3A):55-60, 1997.
26. Pitkaranta A and Hayden FG. What’s New With Common Colds? Complications and Management. Antiviral Therapy 15:117-118, 121-122, 124-128, 1998.
27. Pitkaranta A and Hayden FG. What’s New With Common Colds? Pathogenesis and Diagnosis. AntiviralTherapy 15:50-53, 57-59, 1998.
28. Calfee DP and Hayden FG. New approaches to influenza chemotherapy. Drugs 56:537-553, 1998.
29. Pitkaranta A and Hayden FG. Rhinoviruses are important respiratory pathogens. Ann Med 30:529-537,1998
30. Kaiser L, Couch RB, Galasso GJ, Glezen WP, Webster RG, Wright PF, and Hayden FG. Firstinternational symposium on influenza and other respiratory viruses: summary and overview. Kapalua,Maui, Hawaii, December 4-6, 1998. Antiviral Res 42:149-176, 1999.
31. Gubareva LV, Kaiser L, and Hayden, FG. Influenza virus neuraminidase inhibitors. Lancet 355:827-835,2000.
32. Munoz FM, Galasso GJ, Gwaltney JM Jr, Hayden FG, Murphy B, Webster R, Wright P, and Couch RB.Current research on influenza and other respiratory viruses: II International Symposium on Influenza andOther Respiratory Viruses. Antiviral Res 46:91-124, 2000.
33. Rotbart HA and Hayden FG. Picornavirus Infections. Arch Fam Med 9:913-922, 2000
34. Hayden, FG. Influenza virus and rhinovirus-related otitis media: potential for antiviral intervention.Vaccine 19:S66-S70, 2001.
35. Schmidt AC, Couch RB, Galasso GJ, Hayden FG, Mills J, Murphy BR, Chanock RM. Current researchon respiratory viral infections: III International Symposium on Respiratory Virus Infections. AntiviralRes 50:157-196; 2001.
36. Gubareva LV and Hayden FG. In: Dodet B and Vicari M (eds) Anti-influenza drugs: implications ofresistance. Emerging Diseases. Emergence and Control of Zoonotic Ortho- and Paramyxovirus DiseasesSymposium Proceedings, John Libbey, Paris, 2001, p121-126.
Bibliography
20
Other
1. Hayden FG. Editorial comment - Herpes genualius. Infect Control 4:74-75, 1983.
2. Hayden FG and JM Gwaltney Jr. Letter: Efficacy of alpha2-interferon against the common cold. N Engl JMed 314:144-149, 1986.
3. Hayden FG. (contributor in Infectious Disease) In: SI Landau (editor-in-chief) International Dictionary ofMedicine and Biology. John Wiley & Sons, New York, 1986.
4. Sperber SJ and FG Hayden. Letter: Antibiotics and chronic obstructive pulmonary disease. Ann Intern Med106:910, 1987.
5. Farr BM, FG Hayden and JM Gwaltney Jr. Letter: Zinc for the common cold. Antimicrob AgentsChemother 32:606-607, 1988.
6. Tunkel AR, JK Crane, and FG Hayden. Letter: Pulmonary Nocardiosis in AIDS. Chest 100:195-6, 1991.
7. Gwaltney JM, Jr. and FG Hayden. Letter: Psychological Stress and the Common Cold. N Engl J Med326:644-45, 1992.
8. Hayden FG. (contributor, Task Force on Viruses) In: J Lederberg, RE Shope, and SC Oaks, Jr. (eds.)Emerging Infections Microbial Threats to Health in the United States. National Academy Press,Washington DC, 1992.
9. McIntosh K, P Halonen, and O Ruuskanen (FG Hayden, participant). Report of a Workshop onRespiratory Viral Infections: Epidemiology, Diagnosis, Treatment, and Prevention. Clin Infect Dis 16:151-64, 1993.
10. Hayden, FG. Meeting Report on IXth International Congress of Virology. International Antiviral News1:141-2, 1993.
11. Participant in Report of an Informal Consultation: Progress in development and use of antiviral drugs andinterferon. World Health Organization, Geneva, Switzerland, March 13-15, 1995, pp. 1-30.
12. Hayden FG. Meeting Report on Options for Control of Influenza III. International Antiviral News 4:112-5, 1996.
13. Hayden FG. Meeting Report: Summary of GG167 studies from the Third Options Meeting. In: Influenza-European Scientific Working Group on Influenza 5:6, September, 1996.Hayden FG. Letter to the Editor:Cost and the Common Cold. Annals of Int Med 126:173-74,1997.
14. Pitkaranta A, Hayden FG. Respiratory Viruses and Acute Otitis Media. Letter: N Engl J Med 340:2001,1999.
15. Advances in the prophylaxis and treatment of influenza illness. (Based on a presentation by Frederick G.Hayden, MD) Am J Managed Care 6,(5 suppl):S247-254, 2000
16. Kaiser L, and Hayden FG. Influenza: Continuing threats and new interventions. International Reports onCommunity Acquired Infections 1:1-11, 2000.
17. Hayden FG and Elliot MJ. Letter to editor: Zanamivir to prevent influenza. N Engl J Med 344:529-30,2001.
18. Ison MG, Hayden FG. Commentary. International Antiviral News 9:24; 2001
Bibliography
21
Bibliography
22
Abstracts and Presentations
1. Hayden FG, WJ Hall, RG Douglas Jr and D Speers. Aerosolized amantadine: pharmacokinetics and safetytesting of normal volunteers. Presented at the Seventeenth Interscience Conference on Antimicrobial Agentsand Chemotherapy, New York, NY., October 13, 1978 [abst #279].
2. Hayden FG. In: JR LaMontange and GJ Galasso (ed.), Report of a workshop on clinical studies of theefficacy of amantadine and rimantadine against influenza virus. J Infect Dis 138:928-931.
3. Hayden FG, WJ Hall, RG Douglas Jr and D Speers. Therapeutic trial of aerosolized amantadine HCl innaturally acquired influenza A virus infection. Presented at the Eighteenth Interscience Conference onAntimicrobial Agents and Chemotherapy, Atlanta, GA., October 3, 1978 [abst #485].
4. VanVoris LP, FG Hayden, RF Betts, RG Douglas Jr and WA Christmas. Oral amantadine and rimantadinetherapy of natural influenza A/USSR/77/H1N1. Presented at the Eighteenth Interscience Conference onAntimicrobial Agents and Chemotherapy, Atlanta, GA., October 3, 1978 [abst #483].
5. Hayden FG and RG Douglas Jr. Enhancement of activity against influenza A viruses by combinations ofantivirals. Presented at the Southern Society for Clinical Investigation, New Orleans, LA., January 20,1979. Clinical Research 26:799A, 1978.
6. Hayden FG, DM Zylidnikov, VI Iljenko and YV Padolka. Comparative therapeutic effect of aerosolized ororal rimantadine HCl in experimental influenza A virus infection. Presented at the Nineteenth InterscienceConference on Antimicrobial Agents and Chemotherapy, Boston, MA., October 2, 1974 [abst #563], andpresented at the Second Meeting of the USA-USSR Working Group on Influenza and Acute RespiratoryDiseases, Baylor College of Medicine, Houston, TX., February 2, 1979. Published in JD Nelson and FGrassi (eds.), Current Chemotherapy and Infectious Disease. American Society for Microbiology,Washington, DC., 1980, pp 1348-1350.
7. Hayden FG, JM Gwaltney Jr and FL Van de Castle. Comparative toxicity of antiinfluenza drugs in healthyadults. Presented at the Southern Section American Federation for Clinical Research, New Orleans, LA.,January 26, 1980. Clinical Res 27:751A, 1979.
8. Hayden FG, D Woerner and JM Gwaltney Jr. Prophylactic activity of intranasal enviroxime in volunteerswith experimental rhinovirus type 39 infection. Presented at the Twelfth International Congress ofChemotherapy, Florence, Italy, July 22, 1981 [abst #321].
9. Hayden FG and BA Anderson. Combined rimantadine and ribavirin therapy of experimental influenza Avirus infection in mice. Presented at the Fifth International Congress of Virology, Strasbourg, France,August 6, 1981 [abst #W7/10].
10. Hayden FG and JM Gwaltney Jr. Antipicornavirus activity of the nitrobenzene compound MDL860.Presented at the Twenty-first Interscience Conference on Antimicrobial Agents and Chemotherapy,Chicago, IL., November 5, 1981 [abst #337].
11. Hayden FG and BA Anderson. Influenza A virus strain differences in antiviral effects of rimantadine andribavirin combinations. Clin Res 29:868A, 1981.
12. Hayden FG and JM Gwaltney Jr. Interferon-alpha2 prevents experimental rhinovirus type 39 infection inadults. Presented at the Twenty-second Interscience Conference on Antimicrobial Agents andChemotherapy, Miami, FL., October 4, 1982 [abst #192].
13. Hayden FG, HE Hoffman and DA Spyker. Differences in amantadine HCl side effects relate to differencesin pharmacokinetics. Presented at the Twenty-second Interscience Conference on Antimicrobial Agents andChemotherapy, Miami, FL., October 5, 1982 [abst #423].
Bibliography
23
14. Hayden FG, BA Anderson and N Pushkarskaya. Combined interferon-alpha2, rimantadine HCl, andribavirin inhibition of influenza A virus replication. Presented at the Twenty-second InterscienceConference on Antimicrobial Agents and Chemotherapy, Miami, FL., October 5, 1982 [abst #444].
15. Powers RD, WM Dotson Jr and FG Hayden. Modification of virus-induced diabetes mellitus in mice byinterferon or airldone. Presented at the Twenty-second Interscience Conference on Antimicrobial Agents andChemotherapy, Miami, FL., October 5, 1982 [abst #448].
16. Farr BM, GL Mandell, FG Hayden and JM Gwaltney Jr. Human polymorphonuclear functions areunaffected by recombinant DNA interferon. Presented at the Southern Section American Federation forClinical Research, New Orleans, LA., January 27, 1983. Clin Res 30:852A, 1982.
17. Powers RD, FG Hayden and JO Hendley. Prolonged survival of type 1 herpes simplex virus in lip careproducts. Clin Res 30:876A, 1982.
18. Clayton MT, FG Hayden, D Innes and CE Hess. Infectious mononucleosis complicated by fatal aplasticanemia. Presented at the Virginia Regional Meeting of the American College of Physicians, Williamsburg,VA., February 20, 1983. VA Med 110:119, 1983.
19. Hayden FG, SE Mills and ME Johns. Human tolerance and histopathological effects of chronic intranasalinterferon-alpha2. Presented at the Second International TNO Conference on the Biology of the InterferonSystem, Rotterdam, The Netherland, April 22, 1983. Published in E DeMeyer and H Schellekens (eds.),The Biology of the Interferon System 1983, Elsevier Science Publishers, Amsterdam, The Netherlands,1983, pp 463-468.
20. Hayden FG, AS Sorenson and JA Bateman. Comparison of the Immulok "Cultureset" kit and virusisolation for detection of herpes simplex virus in clinical specimens. Presented at the Sixty-seventhMeeting of the Association of Clinical Scientist, Charlottesville, VA., May 13, 1983 [abst #7].
21. Farr BM, JM Gwaltney Jr and FG Hayden. Prevention of natural rhinovirus infection by daily intranasalhuman interferon-alpha2. Presented at the Thirteenth International Congress of Chemotherapy, Vienna,Austria, August 31, 1983 [abst #4.7/1-8].
22. Hayden FG and JM Gwaltney Jr. Intranasal interferon alpha2 therapy of experimental rhinovirus type 39infection. Presented at the Twenty-third Interscience Conference on Antimicrobial Agents andChemotherapy, Las Vegas, NV., October 25, 1983 [abst #384].
23. Hayden FG. Prophylaxis and treatment of rhinovirus and influenza A virus infection with interferon. Presented at the Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, LasVegas, NV., October 24, 1983 [abst #122].
24. Van Voris LP, J Bartram, HE Hoffman, LM Shalaby, JC Gaylord, LS Davis and FG Hayden.Comparative pharmacokinetics of rimantadine hydrochloride and amantadine hydrochloride. Presented atthe Twenty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Las Vegas, NV.,October 24, 1983 [abst #684].
25. Gwaltney JM Jr and FG Hayden. Prophylactic efficacy of intranasal RMI-15,731 in experimentalrhinovirus infection. Presented at the Twenty-third Interscience Conference on Antimicrobial Agents andChemotherapy, Las Vegas, NV., October 26, 1983 [abst #931].
26. Hayden FG and JM Gwaltney Jr. Human interferon-alpha2 prophylaxis and therapy of respiratory viralinfections. Presented at the Sixth International Congress of Virology, Sendai, Japan, September 5, 1984[abst #W35-1].
Bibliography
24
27. Hayden FG and JM Gwaltney Jr. Human interferon-alpha2 prophylaxis and therapy of respiratoryinfections. Presented at the Pharmacological and Clinical Approaches to Herpes Virus and VirusChemotherapy Meeting, Oiso, Japan, September 13, 1984 [abst #VII-8].
28. Winther B, DJ Innes, SE Mills and FG Hayden. Nasal mucosal responses to recombinant leukoctye Ainterferon in healthy adults. Presented at the Twenty-fourth Interscience Conference on AntimicrobialAgents and Chemotherapy, Washington, DC., October 9, 1984 [abst #919], and at the Third InternationalTNO Meeting on the Biology of the Interferon System, Heidelberg, West Germany, October 24, 1984 [abst#E-30].
29. Salata RA, FG Hayden, J Rubenstein, DHM Groschell and RP Wenzel. Acute febrile cerebrovasculitis:clinical and laboratory features. Presented at the Twenty-fourth Interscience Conference on AntimicrobialAgents and Chemotherapy, Washington, DC., October 10, 1984 [abst #762].
30. Geist FC and FG Hayden. Comparative sensitivity of MRC-5 fibroblast and fetal tonsil cell strain forisolation of rhinoviruses from clinical specimens. Presented at the Annual Meeting of the AmericanSociety for Microbiology, Las Vegas, NV., March 5, 1985 [abst #T1].
31. Hayden FG and HE Hoffman. Single-dose pharmacokinetics and nasal mucus penetration of amantadineHCl and rimantadine HCl in adults. Presented at Viratik-UCLA Symposium on Options for the Control ofInfleuzna, Keystone, CO., April 21, 1985 [abst #1847], J Cell Biochem 9C:276, 1985.
32. Hayden FG. Clinical applications of antiviral agents for chemoprophylaxis and therapy of respiratory viralinfections. Presented at the First International TNO Conference on Antiviral Research, Rotterdam, TheNetherlands, May 3, 1985 [abst #49].
33. Hayden FG. Combinations of antiviral agents for treatment of influenza virus infections. Presented at theVirology Group Symposium of the British Society for Antimicrobial Chemotherapy, Bath, UnitedKingdom, July 5, 1985.
34. Hayden FG. Clinical studies of rimantadine hydrochloride in the United States. Presented at the D.I.Ivanosky Institute for Virology Symposium on the Molecular Biology of Hepatitis and Influenza Viruses.Moscow, USSR., September 25, 1985.
35. Hayden FG, JM Gwaltney Jr and JK Albrecht. Intranasal interferon-alpha 2 prophylaxis of respiratoryillnesses in families. Presented at the Meeting of the American Federation of Clinical Research,Washington, DC., May 4, 1985, and at the TNO-ISIR Meeting on the Interferon System, ClearwaterBeach, FL., October 18, 1985. Clin Res 33:404A, 1985.
36. Gaffey MJ, JM Gwaltney Jr, WE Dressler, JV Sorrentino and FG Hayden. Intranasal atropine methonitratetreatment of experimental rhinovirus (RV) colds. Presented at the Twenty-fifth Interscience Conference onAntimicrobial Agents and Chemotherapy, Minneapolis, MN., September 29 - October 3, 1985 [abst #847].
37. Gaffey MJ, SE Mills and FG Hayden. Histologic effects of intranasal interferons in mice. Presented at theTNO-ISIR Meeting on the Interferon System, Clearwater Beach, FL., October 16, 1985.
38. Hayden FG. Use of interferons for prevention and treatment of respiratory virus infections. Presented at theUniversity of California-San Francisco Symposium, New Directions in Antiviral Chemotherapy , SanFrancisco, CA., November 7, 1985 [abst page #16] and the Annual Conference II of the Inter-AmericanSociety for Chemotherapy, Tampa, FL., December 9, 1985.
39. Hayden FG. Amantadine-rimantadine in influenza: clinical pharmacology. Presented at the Federation ofAmerican Societies for Experimental Biology, Seventieth Annual Meeting, St. Louis, MO., April 14,1986.
Bibliography
25
40. Hayden FG, JM Gwaltney Jr and RJ Colonno. Effect of intranasal rhinovirus receptor monoclonal antibodyon the course of experimentally induced rhinovirus type 39 infection in man. Presented at the AnnualMeeting of the American Society for Virology, Santa Barbara, CA., June 22-26, 1986.
41. Hayden FG, DJ Innes, SE Mills and PA Levine. Long-term tolerance of intranasal recombinant interferon-betaser in man. Presented at the 1986 Annual Meeting of the International Society for Interferon Research,Espoo, Finland, September 5, 1986. Journal of Interferon Research 6(1):31, 1986, and In: Cantrell K, HSchellekens (eds.), This Biology of the Interferon System 1986 , Martinus Nijhoff Publishers, Dordrecht,The Netherlands, 1987, pp 449-455.
42. Creticos CM, DS Stein, GG Jackson, J Bernstein, T Sorg, G Schiff and FG Hayden. Oral ribavirintreatment of influenza A and B. Presented at the Twenty-sixth Interscience Conference on AntimicrobialAgents and Chemotherapy, New Orleans, LA., September 28 - October 1, 1986 [abst #91].
43. Geist F, JA Bateman and FG Hayden. In vitro activity of zinc salts against human rhinoviruses. Presentedat the Twenty-sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans,LA., September 28 - October 1, 1986 [abst #392].
44. Mifflin TE, J Bowden, M Lovell, J Savory, D Groschel, F Hayden, D Burns. Isolation and use of a DNAprobe for rapid detection of cytomegalovirus. Presented at the American Association for ClinicalChemists, Chicago, Ill., July 17, 1986 [abst #609]. Clinical Chemistry 32:1172, 1986.
45. Bowden J, TE Mifflin, M Lovell, J Savory, D Groschel, F Hayden, DE Bruns. Comparison ofradioisotopic and non-isotopic DNA probes for cytomegalovirus DNA. American Association for ClinicalChemistry and Canadian Society of Clinical Chemists, Chicago, Ill., July 17, 1986 [abst #620]. ClinicalChemistry 32:1175, 1986.
46. Hayden FG, DL Kaiser and JK Albrecht. Intranasal interferon-alfa-2b treatment of natural rhinovirus colds.Presented at the Seventh International Congress of Virology, Edmonton, Canada, August 13, 1987 [abst#R32.12, p. 218]. Clin Res 35:477A, 1987.
47. Sperber SJ, JM Gwaltney Jr, DL Kaiser and FG Hayden. Tolerance and efficacy of recombinant intranasalinterferon-beta serine in preventing rhinovirus colds. Presented at the Meeting of the American Federationfor Clinical Research, San Diego, CA., May 1-4, 1987. Clin Res 35:491A, 1987.
48. McBride TP, WJ Doyle, F Hayden and J Gwaltney. Eustachian tube response to a provocative rhinoviruschallenge. Presented at the Fourth International Symposium on Recent Advances in Otitis Media, BayHarbour, FL., June 1-4, 1987.
49. Sperber SJ and FG Hayden. Comparative in vitro activity of recombinant alpha and beta interferons againstrhino- and coronavirus. Presented at the Twenty-seventh Interscience Conference on Antimicrobial Agentsand Chemotherapy, New York, NY., October 4-7, 1987 [abst #500].
50. Sperber SJ, JM Gwaltney Jr, JV Sorrentino and FG Hayden. Pseudoephedrine alone or combined withibuprofen as treatment for experimental rhinovirus colds. Presented at the Twenty-seventh InterscienceConference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987 [abst #501].
51. Geist F, I McAuliffe, J McAuliffe, J Gwaltney and FG Hayden. Etiologies of acute respiratory virusinfections in ambulatory children in Fortaleza, Brazil. Presented at the Twenty-seventh InterscienceConference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987 [abst #901].
52. Stokes CE, JM Bernstein, T Herchline, S Kyger and FG Hayden. Rapid diagnosis of influenza A and B by24 hour shell vial and chamber slide fluorescent focus assays. Presented at the Twenty-seventh InterscienceConference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987 [abst #910].
Bibliography
26
53. Hechemy KE, JA Fox, DHM Groshell, FG Hayden and RP Wenzel. The use of immunoblot to confirmserodiagnostic test results in patients with Rickettsial diseases. Presented at the Twenty-seventhInterscience Conference on Antimicrobial Agents and Chemotherapy, New York, NY., October 4-7, 1987[abst #1247].
54. Sperber SJ, JM Gwaltney Jr, DL Kaiser and FG Hayden. Tolerance and efficacy of recombinant intranasalinterferon-beta serine in preventing experimental and natural rhinovirus colds. Presented at the 1986 AnnualMeeting of the International Society for Interferon Research, Washington, DC., November 2-6, 1987.Journal of Interferon Research 6(1):691, 1987.
55. Hayden F, D Innes, S Mills and P Levine. Intranasal tolerance of recombinant interferon-alfa Con1 inhealthy volunteers. Presented at the Second International Conference on Antiviral Research, Williamsburg,VA., April 13, 1988. Program and Abstracts, Antiviral Research, Vol. 9, pg 122. Jan/Feb 1988.
56. Hayden FG. Antiviral chemoprophylaxis and therapy of influenza virus infections. Presented at theAntivirals-88 International Symposium: Basic and Clinical Approaches to Virus Chemotherapy, Helsinki,Finland, June 19-22, 1988. Final Progam Antivirals-88, pg 67.
57. Sperber SJ, BV Smith and FG Hayden. Preliminary experience with a live and heat-inactivated varicellavaccine in healthy seropositive adults. Program and Abstracts of the Twenty-eighth Interscience Conferenceon Antimicrobial Agents and Chemotherapy, Los Angeles, CA., October 23-26, 1988 [abst #728].
58. Harmond MW, S-P Wu, FG Hayden and AP Kendal. Development of an antiviral resistance screeningassay for type A influenza viruses. Presented at the Twenty-eighth Interscience Conference onAntimicrobial Agents and Chemotherapy, Los Angeles, CA., October 23-26, 1988 [abst #217].
59. Hayden FG. Treatment of respiratory viral infections. Presented at the Second Triennial Conference on NewDirections in Antiviral Chemotherapy, San Francisco, CA., November 3, 1988. Syllabus, pg. 65-96.
60. Arruda E de, J McAuliffe, D Kaiser, F Hayden and J Gwaltney Jr. The morbidity of respiraotry illness inyoung children in a slum in northeast Brazil. Presented at the American Federation for Clinical Research,Washington, DC., February 1-3, 1989. Clinical Res 37:19A, 1989.
61. Hayden FG, W Soo and A Hay. Failure of rimantadine prophylaxis due to transmission of drug-resistantinfluenza A virus in families. Presented at the American Federation for Clinical Research, Washington,DC., April 30, 1989. Clinical Res 37:430A, 1989.
62. Hsia J, GL Simon, AL Goldstein, P Naylor, MB Sztein and FG Hayden. Immune activation duringrhinovirus colds. Presented at the American Federation for Clinical Research, Washington, DC., April 30,1989. Clinical Res 37:431A, 1989.
63. Arruda E, TE Mifflin, B Winther and FG Hayden. Detection of rhinovirus infection in situ hybridization. Presented at the Annual Meeting of the American Society for Microbiology, New Orleans, LA., May 14-18, 1989 [abst #T45].
64. Hayden FG. Clinical significance of rimantadine resistance in influenza A viruses. Presented at theSymposium on Antiviral Therapy of Influenza A Virus Infections. Carmel, California, August 24, 1989.
65. Hayden FG. Treatment of respiratory viral infections. Presented at the American Society for MicrobiologyWorkshop on Antiviral Chemotherapy. Houston, Texas, September 17, 1989.
66. Hayden FG. Efficacy of Intranasal R 77975 for the prevention of experimentally Induced rhinovirusinfection and illness. Presented at the Third International Conference on Antiviral Research, Brussels,Belgium, April 26, 1990 [abst #122].
Bibliography
27
67. Hayden FG. Prevention and treatment of influenza. Presented at 1990 ALA/ATS/IUATLD WorldConference on Lung Health, Boston, Mass., May 24, 1990.
68. Arruda E, TE Mifflin, B Winther, FG Hayden, et al. Localization of rhinovirus replication with in situ hybridization. Presented at 1990 Annual Meeting of the American Society for Virology, Salt Lake City,Utah, July 11, 1990.
69. Hayden FG. Prevention and Treatment of Rhinovirus Infections. Presented at the Workshop onAntiviral Agents, 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, Atlanta,Georgia, October 21, 1990.
70. Hayden FG. Management of Influenza: Therapeutic Issues. Presented at the30th Interscience Conferenceon Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 22, 1990.
71. Whitley R, C Liu, R Pollard, F Hayden, et al. Acyclovir versus vidarabine therapy of disseminated herpeszoster in the immunocompromised host. Presented at the 30th Interscience Conference on AntimicrobialAgents and Chemotherapy, Atlanta, Georgia, October 21-24, 1990 [abst# 728].
72. Hayden F, R Belshe, R Clover, A Hay, and S Pyke. Therapeutic efficacy of rimantadine HCI andrelationship to shedding of drug-resistant influenza A virus. Presented at the 30th Interscience Conferenceon Antimicrobial Agents and Chemotherapy, Atlanta, Georgia, October 21-24, 1990 [abst# 1146].
73. Hayden F. Clinical importance of drug resistance in influenza viruses. Presented at the Fourth InternationalConference on Antiviral Research, New Orleans, Louisiana, April 21-26, 1991.
74. Last-Barney K, SD Marlin, C Cahill, R Jejer, D Fortugno-Erikson, M O'Neill, F Hayden, and VJMerluzzi. A soluble form of intercellular adhesion molecule-1 inhibits rhinovirus infection. Presented atthe Fourth International Conference on Antiviral Research, New Orleans, Louisiana, April 21-26, 1991.Antiviral Res 15 (suppl 1): 107, 1991 [abst # 119].
75. Sperber SJ, BV Smith, and FG Hayden. Serologic response and reactogenicity to booster immunization ofhealthy seropositive adults with live or inactivated varicella vaccine.Presented at the Frontiers in Vaccine Research International Symposium at Hanasaari, Espoo, Finland,September 9-11, 1991.
76. Arruda E, C Crump, S Marlin, V Merluzzi, and F Hayden. Anti-rhinovirus activity of soluble intercellularadhesion molecule-1 in cell cultures and organ cultures of human respiratory epithelium. Presented at the31st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 29-October 2, 1991 [abst #771].
77. Hayden FG. Update on treatment of respiratory viral infections. Presented at the Third TriennialSymposium on New Directions in Antiviral Chemotherapy, San Francisco, California. November 14-16,1991.
78. Turner RB and FG Hayden. Efficacy of oral WIN 54954 for the prophylaxis of experimental rhinovirusinfection. Presented at the Fifth International Conference on Antiviral Research, Vancouver, Canada. March 8-13, 1992. Antiviral Res 17(suppl 1): 92, 1992 [abst #91].
79. Hayden FG. Antivirals in common cold. Presented at the First International Meeting on UpperRespiratory Tract Infections (FIURT), Malta. April 28, 1992.
80. Hayden FG. What are the problems with antiviral agents and what are the prospects for new agents? Presented at the SKB Anti-infective Conference:Controversies in Infectious Disease, Tucson, AZ,September 10-12, 1992.
Bibliography
28
81. Hayden F. Development of antiviral-resistant mutants during rimantadine therapy. Presented at theInternational Scientific Conference Options for the Control of Influenza II, Courchevel, France. September26-October 2, 1992.
82. Hayden F. Drug resistance in respiratory viruses. Presented at the Symposium on Significance of AntiviralResistance in Human Diseases for the 32nd Interscience Conference on Antimicrobial Agents andChemotherapy, Anaheim, California. October 11-14, 1992.
83. Hayden F, J. Treanor, and J. Harris. Multi-dose oral LY217896 for prevention of experimental humaninfluenza A virus infection and illness. Presented at the 32nd Interscience Conference on AntimocribialAgents and Chemotherapy, Anaheim, California. October 11-14, 1992 [abst #407].
84. Arruda E and Hayden FG. Detection of human rhinovirus RNA in nasal washes by polymerase chainreaction (PCR). Presented at the 32nd Interscience Conference on Antimicrobial Agents and Chemotherapy,Anaheim, California. October 11-14, 1992 [abst #1239].
85. Jernigan JA, FG Hayden, DHM Groschel, and BM Farr. Adenovirus type 8 epidemic keratoconjunctivitis(EKC) in an eye clinic: risk factors and control. Presented at the 32nd Interscience Conference onAntimicrobial Agents and Chemotherapy, Anaheim, California. October 11-14, 1992 [abst #1411].
86. Skoner DP, WJ Doyle, F Hayden, CA Buchman, JT Seroky, and P Fireman. Otitis media (OM) as amanifestation of experimental influenza A virus infection. Presented at the Society of Pediatric Research,Washington, D.C. May 3-6, 1993 [abst #1083].
87. Hayden F, A Elkhatieb, J DiGennario, and D Riker. Efficacy and safety of naproxen in the treatment ofnaturally occurring colds. Presented at the IX International Congress of Virology, Glasgow Scotland,August 12, 1993 [abst # W53-2].
88. Hayden F, A Elkhatieb, G Hipskind, and D Woerner. Middle ear abnormalities during natural rhinoviruscolds in adults. Presented at the IX International Congress of Virology, Glasgow, Scotland, August 12,1993 [abst # P53-3].
89. Hayden FG. Respiratory viral infections in transplant patients. Presented at the North AmericanTransplant Infectious Disease Symposium, Boston, MA, November 17-19, 1993.
90. Hayden F, B Rollins and L Madren. Anti-influenza virus activity of 4-guanidino-2, 4-dideoxy-2,3-dehydro-N-acetylneuraminic acid in vitro. Presented at Seventh International Conference on AntiviralResearch, Charleston, SC, February 27- March 4, 1994. Antiviral Res 23(suppl 1):133, 1994 [abst #184].
91. Hayden FG. In vitro studies of 4-guanidino Neu5Ac2en: activity in human respiratory epithelium andpotential for resistance development. Presented at the Sialidase Workshop, Rigi Kaltbad, Switzerland,April 18-19, 1994.
92. Hayden FG. New and emerging viral infections. Presented at the American College of Physicians CurrentConcepts of Clinical Infectious Diseases, Charlottesville, VA, April 13-15, 1994.
93. Hayden FG. The case for and against rimantadine and amantadine. Presented at AGS/AFAR AnnualMeeting, Los Angeles, CA, May 19, 1994.
94. Arruda E, TR Boyle, B Winther, DC Pevear, MJ Gwaltney, Jr., and FG Hayden. Localization of humanrhinovirus (HRV) replication in the upper respiratory tract of humans by in situ hybridization (ISH). Presented at the American Society for Virology 13th Annual Meeting, Madison, Wisconsin, July 9-13,1994 [abst #W23-5].
95. Hayden F, M Lobo, J Esinhart, and B Hussey. Efficacy of 4-guanidino Neu5Ac2en in experimental
Bibliography
29
human influenza A virus infection. Presented at the 34th Interscience Conference on Antimicrobial Agentsand Chemotherapy Meeting, Orlando, FL, October 4-7, 1994 [abst #H35].
96. Blumberg EA, SC Brozena, PC Stutman, C Crumb, J Fitzpatrick, J Alpern, A Gash, and FG Hayden. Immunogenicity and efficacy of influenza vaccine in heart transplant recipients. Presented at the InfectiousDiseases Society of American, Orlando, FL, October 7-9, 1994 [abst #218].
97. Hayden FG. Nosocomial respiratory viral infections. Presented at the Eighteenth Annual Symposium forClinicians on Hospital Infection Control, Charlottesville, VA, November 3-4, 1994.
98. Hayden FG. Update on antiviral therapy of influenza and rhinovirus infections and other respiratory viralinfections. Presented at the Fourth Triennial Symposium on New Directions in Antiviral Chemotherapy,San Francisco, CA, November 10-12, 1994.
99. Hayden FG. Anti-influenza virus activity of the novel neuraminidase inhibitor 4-guanidino-Neu5Ac2en. Presented at the Second Annual Meeting on Antivirals: Genetic Approaches and Clinical Developments,Washington DC, November 17-18, 1994.
100. Hayden FG. Evaluation of candidate antiviral compounds in experimental human influenza. Presented atthe 28th Annual ASCEPT Meeting, Auckland, New Zealand, December 5-7, 1994.
101. Hayden FG. Human studies of resistance in influenza virus. Presented at the Consensus Symposium onAntiviral Resistance, Hamilton, Bermuda, December 8-10, 1994.
102. Hayden FG. Antiviral agents for respiratory viral inections. Presented at World Health OrganizationMeeting on the Progress in the Development and Use of Antiviral Drugs and Interferon, Geneva, March 13-15, 1995.
103. Hayden FG, JJ Treanor, J Esinhart, CU Eason, EK Hussey. Twice daily intranasal GG167 forexperimental influenza A. Presented at the Eighth International Conference on Antiviral Research, SanteFe, New Mexico, April 23-28, 1995. Antiviral Res 26(3):A300, 1995 [abst #140].
104. Hayden FG. Antiviral drug resistance. Presented at the 95th General Meeting American Society forMicrobiology, Washington D.C., May 25, 1995.
105. Fireman P, DP Skoner, WJ Doyle, J Seroky, F Hayden, JM Gwaltney. Effect of rhinovirus 39 (RV) andinfluenza virus (FLU) infections on the lower airways in allergic rhinitis (AR) and non-AR subjects. Presented at the 51st Annual Meeting of American Academy of Allergy and Immunology, February 24-March 1, 1995. Allergy Clin Immunology 95:300, 1995 [abst #994].
106. Hayden FG. Combination antiviral therapy for respiratory virus infections. Presented at ConsensusSymposium on Combined Antiviral Therapy, Lisbon, Portugal, July 1, 1995.
107. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. Presented at the 19thInternational Congress on Chemotherapy, Montreal, Quebec, Canada, July 16-21, 1995, Can J Infect Dis6:267C, 1995 [abst #0505].
108. Hayden F, J Treanor, R Betts, J Esinhart, C Eason, E Hussey. Intranasal GG167 for prevention andtreatment of experimental influenza. Presented at the Joint Meeting of the European Group for Rapid ViralDiagnosis and the European Society Against Viral Diseases, September 13, 1995, Prague, Czech Republic.
109. Hussey E, F Hayden, C Grosse, C Eason, D Morris. Serum and urine GG167 concentrations in healthysubjects inoculated experimentally with influenza A virus. Presented at the 35th Interscience Conferenceon Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 17-29, 1995 [abst #A132].
Bibliography
30
110. Hayden FG. New therapies for respiratory viral infections. Presented at the 33rd Annual Meeting of theInfectious Diseases Society of America, San Francisco, CA, September 17, 1995.
111. Hayden FG. Influenza virus infections. Presented at Emerging Disease: Update 1995, Lisbon, Portugal,October 10, 1995.
112. Rakes GP, E Arruda, JM Ingram, GE Hoover, FG Hayden, TAE Platts-Mills, PW Heymann. Humanrhinovirus in wheezing children: relationship to serum IGE and nasal eosinophil cationic protein. Presented at American Academy of Allergy and Asthma, and Immunology. New York, NY, February 1995Am J of Resp Crit Care Med 1995;151 [abst #362].
113. Rakes GP, Arruda E, Ingram JM, Hoover GE, Hayden FG, Platts-Mills TAE, Heymann PW. Assessmentof viral pathogens and eosinophil cationic protein in nasal washes from wheezing infants and children. JAllerg Clin Immunol 1995;95 [abst #477].
114. Hayden FG. How do you diagnose this and is there really a new treatment for flu? Presented at Update`96, Whistler, British Columbia, February 3-6, 1996.
115. Hayden FG. Critical respiratory viral pathogens. Presented at the Society of Critical Care Medicine(SCCM), New Orleans, LA, February 5-9, 1996.
116. Hayden FG, Hussey EK, Eason CU. Efficacy of GG167 administered as intranasal sprays in healthy susceptible volunteers following influenza A and B challenge. Presented at the Third International
Conference on Options for Control of Influenza, Cairns, Australia, May 4-9, 1996 [abst #S4-1, p 25]
117. Hayden FG, Rollins BR, Hirst HM, Hussey EK. GG167 susceptibility of influenza A viruses recoveredafter GG167 administration. Presented at the Third International Conference on Options for Control ofInfluenza. Cairns, Australia, May 4-9, 1996, [abst #W4-6, p36 ]
118. Hayden, FG. Viral infections of the upper and lower respiratory tract and sinusitis. Presented at EighthAnnual Course, Infectious Diseases '96, Washington, DC, May 17-19, 1996.
119. Hayden, FG. Influenza virus resistance to amantadine and rimantadine. Presented at Medical VirologyCub Satellite Symposium, Hamilton, Ontario, July 12, 1996.
120. Fritz, RS, Lobo MC, Alvord WG, Strober W, Straus SE and Hayden FG. Cytokine elaboration andsymptom pathogenesis during acute influenza a virus infection. Presented at the 36
th Interscience
Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 16-19, 1996.[abst #H46, p.171]
121. Rotbart HA, Brennan PJ, Fife KH, Romerro JR, Griffin JA, McKinley MA, Hayden FG. Enterovirusmeningitis in adults. Presented at the 36
th Interscience Conference on Antimicrobial Agents and
Chemotherapy, New Orleans, Louisiana, September 16-19, 1996. [abst #H41 p.170]
122. Hayden F, Osterhaus A, Treanor J, Aoki F, Keene O, and GG167 Study Group. Phase II studies of thetherapeutic efficacy and safety of GG167 in uncomplicated influenza. Presented at the 36
th Interscience
Conference on Antimicrobial Agents and Chemotherapy, New Orleans, Louisiana, September 16-19, 1996.[abst #H45 p.171]
123. Hayden, FG. Update on clinical studies with the novel neuraminidase inhibitor GG167. Presented atIBC’s International Industry Conference on Influenza and Other Respiratory Diseases, Washington, DC,September 26-27, 1996.
124. Hayden, FG. Clinical importance of amantadine resistance in influenza viruses. Presented at the 4thAnnual Work Group Meeting on Improving the Performance of Influenza and Pneumococcal Vaccines in
Bibliography
31
Adults, Institute of Aging and Immunology, Washington, DC, October 8-9, 1996.
125. Hayden, FG. Update on GG167. Presented at the 4th Annual Work Group Meeting on Improving thePerformance of Influenza and Pneumococcal Vaccines in Adults, Institute of Aging and Immunology,Washington, DC, October 8-9, 1996.
126. Hayden, FG. Update on treatment of influenza. Presented at the 7th Swiss Glaxo Wellcome WorkshopChallenge in Virology, Saanen-Gstaad, Switzerland, January 10-12, 1997.
127. Hayden, FG. Influenza virus neuraminidase inhibitors. Presented at the Seventh International AntiviralSymposium, Sydney, Australia, February 17-19, 1997. [abst #14, p.23]
128. Hayden, FG. Respiratory viruses and new compounds. Presented at Virology: A New Perspective,Canberra, Australia, February 21, 1997.
129. Hayden, FG. Rhinoviruses, ICAM-1 and respiratory tract. Presented at the 36th Annual Swineford Allergy
Conference, Charlottesville, VA , April 18-19, 1997.
130. Arruda E, Pitkaranta A, Witek TJ, Doyle CA, Hayden FG. Etiology and clinical course of common coldsduring autumn months. Presented at American Thoracic Society, San Francisco, CA, May 18, 1997.
131. Hayden, FG. Treatment of non-HIV viral infections. Presented at the Second Conference on New andReemerging Infectious Diseases, Atlanta, GA, June 8, 1997.
132. Hayden, FG. Antivirals for ARI. Presented at the International Conference on Acute Respiratory Infections,Canberra, Australia, July 7-10, 1997.
133. Hayden, FG. Influenza: advances in vaccines and antivirals, including inhaled zanamivir treatment.Presented at the Haartman Seminar, Haartman Institute, Helsinki, Finland, September 4, 1997.
134. Hayden, FG. Respiratory viruses. Presented at the III International Consensus Symposium on NovelDevelopments in Antiviral Therapy, Istanbul, Turkey, September 7-9, 1997.
135. Hayden, FG. Prospects of anti-viral interventions in the airways. Presented at the Annual Congress of theEuropean Respiratory Society, Berlin, Germany, September 24, 1997.
136. Pitkaranta A, Arruda E, Virolainen A, Jero J, and Hayden FG. Detection of rhinovirus, respiratorysyncytial virus and coronavirus RNA in children with acute otitis media. Presented at 37
th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28 - October 1,1997. [abst #H-83, p. 228]
137. Turner RB, Wecker MT, Pohl G, Witek TJ, Marlin S, McNally E and Hayden, FG. Efficacy of solubleICAM-1 (sICAM) for prevention of rhinovirus infection and illness. Presented at 37
th Interscience
Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28 - October 1,1997. [abst #H-85, p. 229]
138. Hayden FG, Lobo M, Treanor JJ, Miller M, Mills RG. Efficacy and tolerability of oral GS4104 for earlytreatment of experimental influenza in humans. Presented at 37
th Interscience Conference on Antimicrobial
Agents and Chemotherapy, Toronto, Canada, September 28 - October 1, 1997. [abst #LB-26, p14]
139. Hayden FG. Antiviral resistance in respiratory viruses. Presented in Symposium on Treatment - ResistantViruses at 37
th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada,
September 26, 1997.
140. Hayden FG. Update on neuraminidase inhibitors. Presented at the 5th Annual Work Group Meeting on
Bibliography
32
Improving the Performance of Influenza and Pneumococcal Vaccines in Adults, Institute of Aging andImmunology, Washington, DC, October 7-8, 1997.
141. Hayden FG. Influenza - New strategies for treatment. Presented at the Fifth Triennial Symposium, NewDirections in Antiviral Chemotherapy, San Francisco, CA, November 13-15, 1997.
142. Hayden, FG. Rhinovirus: New approaches. Presented at the Fifth Triennial Symposium, New Directionsin Antiviral Chemotherapy, San Francisco, CA, November 13-15, 1997.
143. Hayden, FG. What’s new with flu? and Common cold controversies. Presented at the Update ’98,Whistler, B.C., Canada, February 7-10, 1998
144. Hayden, FG. What’s new in treatment of herpes infections. Presented at the Current Concepts of ClinicalInfectious Disease, Charlottesville, VA April 15-17, 1998.
145. Hayden, FG. Influenza neuraminidase inhibitors: A review. Presented at the 1998 Harold C. NeuInfectious Diseases Conference, Seattle, WA, April 30- May 3, 1998.
146. Hayden, FG. Newer treatments and preventive strategies for influenza. Presented at APIC 98 - The25thAnnual Educational Conference & International Meeting, San Diego, CA, May 10-14, 1998.
147. Hayden, FG. Influenza neuraminidase inhibitors: A review. Presented at the Harold C. Neu InfectiousDiseases Conference, Seattle, WA, April 30-May 2, 1998.
148. Hayden, FG. Influenza and Rhinoviruses. Presented at the Tenth Interntional Symposium on Infections inthe Immunocompromised Host, Davos, Switzerland, June 21-24, 1998.
149. Hayden FG. Clinical efficacy of antiviral agents: Influenza neuraminidase inhibitors. Presented at theGroupe d’ Etude et d’ Information sur la Grippe XIIth European Meeting on Influenza and its Prevention,September 17-18, 1998 Biarritz, France.
150. Hayden FG. Antivirals for influenza neuraminidase inhibition: Focus on oral GS4104. Presented inSymposium on Meeting the Challenge of Influenza at the European Respiratory Society Annual Congress,September 22, 1998, Geneva, Switzerland.
151. Hayden FG, Fritz RS, Lobo M, Kinnersley N, Mills RG, and Straus SE. Effects of the oral neuraminidaseinhibitor GS410 on cytokine response during experimental human influenza A virus infection. Presentedat the European Respiratory Society Annual Congress, September 2, 1998, Geneva Switzerland. EuropeanRespiratory Journal 263S:abst #1799, 1998.
152. Hayden, FG. Influenza Neuraminidase Inhibitors. Presented in Symposium on Advances in Treatment andControl of Influenza at the 38
th Annual Interscience Conference on Antimicrobial Agents and
Chemotherapy, San Diego, California, September 27, 1998.
153. Fritz RS, Hayden FG, Calfee DP, Cass LMR, Peng AW, Alvord WG, and Straus SE. Cytokine andchemokine responses during experimental influenza A infection: Effect of intravenous zanamivir. Programand abstracts from the 38
th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy,
San Diego, California, September 26, 1998. [abst # H-57, p 51]
154. Calfee DP, Peng AW, Cass LMR, Lobo M, and Hayden FG. Protective efficacy of intravenous zanamivirin experimental human influenza. Program and abstracts from the 38
th Annual Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Diego, California, September 24-27, 1998. [abst #H-58, p52]
155. Calfee DP, Peng AW, Hussey EK, Lobo M. and Hayden FG. Protective efficacy of reduced-frequency
Bibliography
33
dosing of intranasal zanamivir in experimental human influenza. Program and abstracts from the 38th
Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California,September 24-27, 1998. [abst #H-68, p 334]
156. Treanor JJ, Vrooman PS, Hayden FG, Kinnersley N, Ward P, and Mills RG on behalf of the US oralneuraminidase inhibitor study group. Efficacy of oral GS4104 in treating acute influenza. Program andabstracts from the 38
th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San
Diego, California, September 25, 1998. [abst #LB-4, p 17]
157. Hayden FG, Atmar R, Schilling M, Johson C, Poretz D, Parr D, Huson L, Ward P, and Mills R. Safetyand efficacy of oral GS4104 in longterm prophylaxis of natural influenza. Program and abstracts from the38
th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, California,
September 26, 1998. [abst #LB-6, p18].
163. Hayden FG. When should we treat respiratory virus infections? Presented in Symposium on NewStrategies In Managing Viral Diseases at the 5
th Conference of the Federation of Infection Societies,
Manchester, UK, November 25-27, 1998.
164. Hayden FG. When should we treat respiratory virus infections? Presented at the 5th Conference of the
Federation of Infection Societies, Manchester, UK, November 25-27, 1998. [abst #1.4, p18].
165. Hayden FG. Antiviral treatment of respiratory virus infections. Presented at the Eropean Society forClinical Virology Winter Meeting, Rotterdam, The Netherlands, January 7-9, 1999.
166. Hayden FG. Antiviral treatment of common colds and influenza. Presented at the Annual Congress ofFinnish Medical Society, Helsinki, Finland, January 3-7, 1999.
167. Hayden, FG. New developments in antivirals and vaccines against influenza. Presented at Challenge inVirology, the 9
th Swiss Glaxo Wellcome Workshop, Saanen, Switzerland, January 15-17, 1999.
168. Zambrano JC, Carper HT, Hayden, FG et al. Inflammatory airway responses to experimental rhinovirus-16infection in asthma subjects: Exhaled nitric oxide (NO), soluble ICAM-1, nasal eosinophil catonic protein(ECP). Presented at 1999 American Academy of Allergy and American Thoracic Society InternationalConference, April 23-28, 1999, San Diego, CA
169. Zambrano JC, Carper HT, Hayden, FG et al. Experimental rhinovirus-16 infection in asthma patients:Exhaled nitric oxide (NO)and eosinophil catonic protein (ECP). Presented at 1999 American Academy ofAllergy and American Thoracic Society International Conference, April 23-28, 1999, San Diego, CA
170. Hayden, FG. Advances in influenza management: focus on neuraminidase inhibitors and intranasalvaccine. Presented at the 9
th European Congress of Clinical Microbiology and Infectious Diseases, Berlin
Germany, March 21-24, 1999.
171. Hayden, FG. Influena neuraminidase inhibitors. Presented at the 143rd Meeting of the Society for General
Microbiology, Edinburgh, Scotland, April 12, 1999.
172. Hayden, FG. Influenza neuraminidase inhibitors. Presented at the 15th Annual Clinical Virology
Symposium and Pan American Society for Clinical Virology, Clearwater Beach, FL, May 9-12, 1999.
173. Hayden, FG. Influenza, the continually re-emerging plague. Presented at the 13th Annual Biologic Basis of
Pediatric Practice Symposium, Brian Head, Utah, July 9-11, 1999.
174. Hayden, FG. The genetics of influenza; Implication for vaccine development. Presented at the 13th Annual
Biologic Basis of Pediatric Practice Symposium, Brian Head, Utah, July 9-11, 1999.
Bibliography
34
175. Hayden, FG. Antiviral therapy and chemoprophylaxis for influenza. Presented at the 21st International
Congress of Chemotherapy, Birmingham, UK, July 4-7, 1999. The Journal of AntimicrobialChemotherapy. 44 (Suppl A):13, 1999 [abst #15-67]
176. Hayden FG, Gubareva L, Klein T, Elliott MJ, Hammond J, Ossi M, Sharp S, Monto AS. Inhaledzanamivir for preventing transmission of influenza in families. 39
th ICAAC Final Program, Abstracts and
Exhibits Addendum. San Francisco, CA, September 26-29, 1999
177. Hayden, FG. Influenza: Virulence factors, therapeutic strategies. Presented at the 2nd
Bernese InfectiousDiseases Symposium. Berne, Switzerland. October 21, 1999.
178. Hayden, FG. Status of pleconaril and 3C protease inhibitors for rhinovirus. Presented at the II InternationalSymposium on Influenza and Other Respiratory Viruses. Grand Cayman, Cayman Islands, December 10-12, 1999
179. Gubareva LV, Schallon D, and Hayden FG. Activity of the neuraminidase inhibitor RWJ-270201 (BCX-1812) against influenza A and B viruses in the neuraminidase inhibition assays. Presented at the IIInternational Symposium on Influenza and Other Respiratory Viruses. Grand Cayman, Cayman Islands,December 10-12, 1999.
180. Hayden, FG. Influenza – Epidemiology in clinical practice. Presented at the Influenza Conference, GlobalChallenges – New Treatments. Salt Lake City, UT, January 14, 2000.
181. Hayden, FG. Antivirals for influenza. Presented at the Stockholm Virology Meeting, Stockholm,Sweden, February 3-5, 2000.
182. Hayden FG. Influenza Treatments: Role for neuraminidase inhibitors. Presented at Update 2000, Whistler,British Columbia, Canada, February 7, 2000.
183. Hayden FG. The common cold. Presented at Update 2000, Whistler, British Columbia, Canada, February7, 2000.
184. Hayden, FG. Antiviral agents for influenza. Presented at the Workshop on Treatment of Influenza “NewPerspectives”. Utrecht, Netherlands, February 16, 2000.
185. Hayden, FG. Advances in antiviral management of rhinovirus and influenza infections. Presented attheInternation Symposium on Otitis Media. Annecy, France, February 13-16, 2000.
186. Hayden, FG. Influenza: Advances in Prevention and Treatment. Presented at the Stanford University/PaloAlto Medical Foundation 26
th Winter Course in Infectious Diseases. Vale, Colorado, February 20-25,
2000.
187. Hayden, FG. Rhinovirus: New Insights on Epidemiology, Pathogenesis, and Management. Presented atthe Stanford University/Palo Alto Medical Foundation 26
th Winter Course in Infectious Diseases. Vale,
Colorado, February 20-25, 2000.
188. Hayden, FG. Preventing influenza in acute care settings. Presented at the 4th Decennial International
Conference on Nosocomial and Healthcare-Associated Infections, Atlanta, Georgia, March 8, 2000.
189. Hayden, FG. Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimentalinfluenza A in healthy adult volunteers. Presented at the 9th International Congress on Infectious Diseases,Buenos Aires, Argentina, April 10-13, 2000 [abst #80.018, p 184]
190. Hayden, FG. Current treatment of influenza. Presented at the 9th International Congress on InfectiousDiseases, Buenos Aires, Argentina, April 10-13, 2000 [abst #57.003, p137]
Bibliography
35
191. Hayden, FG. Clinical studies for influenza neuraminidase inhibitors. Presented at the 13th International
Conference on Antiviral Research, Baltimore, MD, April 16-21, 2000. Antiviral Research 46:A26, 2000.
192. Gubareva LV, Tai CY, Mendel DB, Ives J, Carr J, Roberts NA, and Hayden FG. Oseltamivir treatment ofexperimental influenza A/Texas/36/91 (H1N1) virus infection in humans: selection of a novelneuraminidase variant. Presented at the 13
th International Conference on Antiviral Research, Baltimore,
MD, April 16-21, 2000. Antiviral Research 46:A59, 2000 [abst #78].
193. Carr J, Ives J, Roberts N, Kelly L, Lambkin R, Oxford J, Tai CY, Mendel D, and Hayden F. Virologicalassessment in vitro and in vovo of an influenza H1N1 virus with a H274Y mutation in the neuraminidasegene. Presented at the 13
th International Conference on Antiviral Research, Baltimore, MD, April 16-21,
2000. Antiviral Research 46:A59, 2000 [abst #79].
194. Gubareva LV, Webster RG, and Hayden FG. Cross resistance of influenza virus mutants to NA inhibitors:Zanamivir, GS4071, and RWJ-270201. Presented at the 13
th International Conference on Antiviral
Research, Baltimore, MD, April 16-21, 2000. Antiviral Research 46:A54, 2000 [abst #63].
195. Hayden FG, Ward P, and Roberts N. Oral oseltamivir in experimental human influenza B virus infection: Lack of resistance emergence. Presented at the 13
th International Conference on Antiviral Research,
Baltimore, MD, April 16-21, 2000. Antiviral Research 46:A54, 2000 [abst #65].
196. Hayden FG, Treanor J, Qu R, and Fowler CL. Efficacy and safety of the oral neuraminidase inhibitorRWJ-270201 in treating experimental human influenza A infections. Presented at the 3
rd European
Congress of Chemotherapy, Madrid Spain, May 7-10, 2000. Spanish Journal of Chemotherapy 13:22.[abst M188].
197. Hayden FG. New antiviral strategies for management of influenza. Presented at the 10th European
Congress of Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, May 28-31, 2000.Clinical Microbiology and Infection 6 (Suppl 1):250, 2000. [abst #MoS2].
198. Reisinger K, Hayden FG, Whitley R, Dutkowski R, Ipe D, Mills R, Ward P. Oral oseltamivir is effectiveand safe in the treatment of children with acute influenza. Presented at the 10
th European Congress of
Clinical Microbiology and Infectious Diseases, Stockholm, Sweden, May 28-31, 2000. ClinicalMicrobiology and Infection 6 (Suppl 1):250,140, 2000. [abst #WeP257].
199. Hayden FG. Neuraminidase inhibitors for influenza. Pro-and-con debate at the 10th European Congress of
clinical Microbiology and Infectious Diseases, Stockholm, Sweden, May 28-31, 2000.
200. Hayden, FG. New drugs to treat respiratory viral infections. Presented at the New and ReemergingInfectious Diseases: A Clinical Course, Atlanta Georgia, June 3-5, 2000.
201. Drusano GL, Treanor JJ, Fowler CL, Preston SL, Qu R, Natarajan J, Iyer G and Hayden FG. Time to viralclearance after experimental infection with influenza B is related to the cumulative area under the curve ofRWJ-270201. Presented at the 38
th Annual Meeting of the Infectious Disease Society of America,
September 7-10, 2000 New Orleans, LA. [abst #610, p 146].
202. Winther B, Hendley JO, Joyner P, and Hayden FG. Reverse Transcriptase-Polymerase Chain Reaction(RTPCR) for diagnosis of human rhinovirus (HRV) infections in children. Presented at the 40
th
Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto,Canada. [abst #189, p 262].
203. Kaiser L, Fritz RS, Straus SE, Gubareva L, and Hayden FG. Symptom pathogenesis during acuteinfluenza – IL-6 and other cytokine responses. Presented at the 40
th Interscience Conference on
Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #178, p 260].
Bibliography
36
204. Boeckh M, Hayden F, Corey L, and Kaiser L. Detection of rhinovirus RNA in bronchoalveolar lavage inhematopoietic stem cell transplant recipients with pneumonia. Presented at the 40
th Interscience Conference
on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #190, p262].
205. Hayden F, Treanor J, Qu R, and Fowler C. Safety and efficacy of an oral neuraminidase inhibitor RWJ-270201 in treating experimental influenza A and B in healthy adult volunteers. Presented at the 40
th
Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto,Canada. [abst #1156, p 270].
206. Hayden FG, Kim K, Coats T, Blatter M, and Drehobl M. Pleconaril treatment shortens duration ofpicornaviral upper respiratory illness in adults. Presented at the 40
th Interscience Conference on
Antimicrobial Agents and Chemotherapy, September 17-20, 2000, Toronto, Canada. [abst #1161, p 272].
207. Winther B, Hayden FG, Whitley R, Reisinger K, Dutkowski R, Ipe D, Ward P. and Mills R. Oraloseltamivir reduces the risk of developing accute otitis media following influenza infection in children.Presented at the 40
th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17-
20, 2000, Toronto, Canada.[abst #977, p 480]
208. Hayden FG. Influenza neuraminidase inhibitors: Clinical aspects. Presented at Options for the Control ofInfluenza IV, September 23-28, 2000, Crete, Greece. [abst #27, p 8].
209. Hayden FG, Reisinger KS, Whitley R, Dutkowski R, Ipe D, Mills R, and Ward P. Oral oseltamivir iseffective and safe in children for the treatment of acute influenza A and B. Presented at Options for theControl of Influenza IV, September 23-28, 2000, Crete, Greece.[abst #W22-1, p 20]
210. Nedyalkova MS, Hayden FG, Webster RG, and Gubareva LV. Accumulation of subgenomic RNAS ofsegment 6 of influenza A but not B viruses passaged in the presence of neuraminidase inhibitors. Presentedat Options for the Control of Influenza IV, September 23-28, 2000, Crete, Greece. [abst #W23-4, p 24,26].
211. Hayden FG. Update on Influenza. Presented at the 4th Annual Virginia Pulmonary Conference and Research
Symposium, October 7, 2000, Richmond, VA.
212. Hayden FG. Influenza Neuraminidase Inhibitors: Clinical Aspects. Presented at Vaccines 2000 Institute forAdvanced Studies in Aging and Geratric Medicine, October 23, 2000, Washington, DC.
213. Hayden FG. Advances in influenza management. Presented at the 78th Annual Fall Conference, Kansas
City Southwest Clinical Society, October 27, 2000, Kansas City, MO.
214. Hayden FG. Prevention and Treatment, Presented at the American College of Allergy, Asthma &Immunology Annual Meeting, November 2, 2000, Seattle, WA.
215. Hayden FG. Influenza neuriminidase inhibitors: Clinical aspects. Presented at the Eighth InternationalAntiviral Symposium and Workshop, November 19, 2000, Kogoshima, Japan. [abst #S7]
216. Hayden FG. Influenza antivirals in perspective. Presented at the Third International meeting on the Therapyof Infections, December 5, 2000, Florence, Italy.
217. Hayden FG. Recent advances in the prevention and treatment of influenza. Presented at the 11th Swiss
Glaxo Wellcome Workshop: Challenge in Virology, Saanen-Gstaad, Switzerland, January 12, 2001.
218. Hayden FG. What’s new with influenza? Presented at the 27th Winter Course in Infectious Diseases,
Snomass, CO, February 26, 2001.
Bibliography
37
219. Hayden, FG. Viral Pneumonias: A primer. Presented at the 27th Winter Course in Infectious Diseases,
Snomass, CO, March 2, 2001.
220. Hayden FG. Influenza management: advances and unmet needs. Presented at the Antiviral Drug Discoveryand Development Summit, Princeton, NJ, March 28, 2001.
221. Hayden FG. Influenza antivirals in perspective. Presented at the 41st Annual meeting of the Japanese
Respiratory Society, April, 2001, Tokyo, Japan. Journal of the Japanese Respiratory Society 39 (#3Suppl-2):97,2001 [abst #ES 5-3].
222. Hayden FG. In vitro anti-rhinovirus spectrum and potency of BTA188, a novel, oral picornavirus capsidbinder. Presented at the14th International Conference on Antiviral Research, Seattle, WA, April 8-12,2001. Antiviral Research 50:A75, 2001. [abst #127]
223. Hayden FG. Influenza antivirals in perspective. Presented at the Royal Society Discussion Meeting on theorigin and control of pandemic influenza, London, April 26, 2001.
224. Hayden FG. Influenza diagnostics. Presented at the 7th Conference of the International Society of Travel
Medicine, Innesbruck, Austria, May 27-31, 2001 [abst # PL04.03]
225. Hayden FG. Anti-influenza chemoprophylaxis and treatment for travelers. Presented at the 7th conference
of the International Society of Travel Medicine, Innesbruck, Austria, May 27-31, 2001 [abst # SY11.03]
226. Hayden, FG. Treating and preventing influenza with neuraminidase inhibitors. International Journal ofAntimicrobial Agents 17(Suppl. 1) S56, 2001. [abst #S20.04]
227. Kaiser L, Ward P, Mahoney P, Hayden FG. Oral oseltamivir reduced complications and hospitalizationsresulting from influenza infection: a meta-analysis. International Journal of Antimicrobial Agents17(Suppl. 1) S117, 2001. [abst #P24.204]
228. Hayden FG. New drugs to treat viral respiratory infections. Presented at the New and ReemergingInfectious Diseases: A Clinical Course, Atlanta, GA, June 8-10, 2001
229. Hayden FG. Influenza. Presented at the 5th Congress of Infectious Diseases, Cartagena De Indias,
Colombia, June 13-15, 2001.
230. Gomes R, Cintra OAL, Gubareva L, Hayden FG, Arruda E. Development of a duplex RT-PCR assay forthe detection of influenza virus in clinical samples and comparison with quick-vue and viral isolation inshell vial. Presented at the American Society for Virology 20
th Annual Meeting, Madison, Wisconsin,
July 21-25, 2001. [abst #P5-5]
231. Macedo IS, Borges EB, Silva ML, Winther B, Arruda LK, Camara AA, Hayden FG, Arruda E. Development and application of an assay based on RT-PCR and hydridization for the detection of humancoronaviruses OC43 and 229E. Presented at the American Society for Virology 20
th Annual Meeting,
Madison, Wisconsin, July 21-25, 2001. [abst #P5-6]
232. Hayden FG. New non-HIV antivirals. Presented at the 39th Annual meeting of the Infectious Diseases
Society of America, San Francisco, CA, October 25-28, 2001. [abst #S77]
233. Hayden FG, Kim K, Hudson S and Villano A. Pleconaril treatment provides early reduction of symptomseverity in viral respiratory infection (VRI) due to picornaviruses. Presented at the 39
th Annual meeting of
the Infectious Diseases Society of America, San Francisco, CA, October 25-28, 2001. [abst #414]
